**ROLE OF BIOMARKERS IN MEDICAL SCIENCE**

**SANCHAYITA BASU1, RISHI BHATTACHARYA2, DR. BIPIN KUMAR SHARMA1\***

1Department of Microbiology, Tripura University, Suryamaninagar, Agartala-799022

2Department of biomedical Science and Technology, The school of Biological Sciences, Ramakrishna Mission Vivekananda Educational Research Institute, Belur Math, Howrah, West Bengal- 711202

**\*Corresponding author’s address:**Dr. Bipin Kumar Sharma, Assistant Professor, Department of Microbiology, Tripura University, Suryamaninagar, Agartala, Tripura 799022.

Email: [bksharma@tripurauniv.ac.in](mailto:bksharma@tripurauniv.ac.in); Phone no. 9862175788

**INTRODUCTION:**

In medical diagnostics Biomarker is a metric that reflects severity, extent or presence of some disease state and in some cases reflects the prognosis of patient (Lim *et.al.*, 2015). In 2001, a working group of the National Institutes of Health (NIH) coined the term biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” (Strimbu and Tavel, 2010). It provides a dynamic, powerful and accurate approach to understand a wide spectrum of disease epidemiology, screening, randomized clinical trials, diagnosis and prognosis. From the earliest manifestations to the extreme stages Biomarkers can reflect the entire spectrum of disease accurately and elaborately depicting all the intermediate stages (Mayeux, 2004). Throughout Generation a varied array of Biomarkers are used by epidemiologists, scientists, diagnostic experts and physicians to study human disease. The application of biomarkers in the diagnosis and management of cardiovascular disease, immunological disorders, infections and genetic disorders, Cancers ,Neurological and Neuropsychiatric disorders and Autoimmune disorders are well known (Perera and Weinstein, 2000; Dunckley *et.al.*, 2005; Gutierrez *et.al.*, 2020; Prince, 2005). To explain briefly biomarkers can be regarded as characteristic biological properties which can be found and measured in parts of the body such as blood or tissue or they can be an external agent that is introduced into an organism to examine a particular organ function or other aspects of health. A common example is presence of antibodies indicates a particular infection and the level of Biomarker especially those detected in the body fluids gives an indication about progression and path physiology of the disease. These biomarkers can be Molecules, Gene products, hormones, Organic metabolites, complex organ functions or Cytoskeleton changes and sometimes a combination of two or more such factors (Lim *et.al.*, 2015). Diagnosis and treatment of diseases (especially multifactor related complex diseases) in molecular level is driven by a biomarker based approach. Past decade showed a rapid discovery of Biomarkers driven by therapeutic modalities such Precision and Regenerative medicine guided by various branches of “Omics” along with computational technology such as AI (Artificial intelligence), machine learning and Deep learning(Bravo *et.al.*, 2020). The selection of discriminating features related to any disease/ abnormal state via a biomarker is known as feature selection in machine learning languages. Applications of this latest technique are very uniquely designed to maintain the performance in a high throughput level. The discovery of biomarkers with application of such advance technology not only gives a accuracy measure for detection purpose but also the process has also become very fast(compared to conventional detection methods). It can be said that biomarkers will be the most widely applied upcoming detection procedure for medical assessment and will be preferred by clinicians and technicians. With fluctuations in expression biomarkers prominently and distinctively distinguishes between healthy state and compromised state of a biological system. The stages of any disease from primary to advance state and the extent of its expression are an important data to collect before providing any treatment.

This chapter will focus on the Classification of Biomarkers and their correlation with a wide repertoire of diseases along with their role in Precision medicine. The chapter also will deeply provide an insight to the types of biomarkers related to broadly classified diseases as well including cancer, cardiomyopathy, neurodegenerative, neuropsychiatric, infectious, hepatic, genetic and autoimmunity diseases.

**1. Cancer Biomarkers**: Biomarkers for cancer are measurable indicator of risk, prognosis and diagnosis of Cancers. The indicators include a variety of biomolecules such as Nucleic acid, proteins which are isolated from clinical samples such as blood (serum and plasma), saliva, swabs, tissue biopsy and CSF. On the other hand, genetic testing is conventionally different from cancer biomarker testing. This technique is used for detecting germline genetic variations which can be associated with hereditary cancer and/or cancer-associated syndrome (Sarhadi and Armengol 2022).

**1.1Brain and Nervous system Cancers**: According to the data published by American Cancer society (<https://www.cancer.org/cancer/types.html>) chance factor of a person to develop a malignant tumor of Central Nervous System (CNS) i.e. the brain or spinal cord in their lifetime is less than 1% and is more prevalent in males than in females . There are various types of Brain and Nervous system cancers this includes - 1) Gliomas 2) Meningiomas 3) Schwanomas 4) Pituitary tumors 5) Pineal gland tumors 6) Primary Central Nervous system (CNS) Lymphoma 7) Medulloblastomas 8) Craniophyrangeomas 9) Choroid Plexus tumor. In India The five most frequent brain and Nervous system tumors were MB  (11.4%), ependymal tumors  (4.8%), craniopharyngioma  (9.7%), astrocytoma  (47.3%) and nerve sheath tumors  (4.1%)10 whereas in USA and Europe the epidemiology shifts where gliomas take upto 78% of Brain and Central Nervous system tumors([https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Brain-Tumors- :~:text=Gliomas%20are%20the%20most%20prevalent,oligodendroglial%20cells%20(or%20oligos).](https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Brain-Tumors-%20:~:text=Gliomas%20are%20the%20most%20prevalent,oligodendroglial%20cells%20(or%20oligos).) and 86.0% astrocytic (24% low grade, 63% high grade and 13% glioma NOS), 3.6% ependymal (85% low grade), 4.1% Embryonal tumours, 6.4% oligodendroglial (74% low grade) and (0.1%) choroid plexus carcinoma (Crocetti *et.al.* 2012). Though imaging studies Through CT scans and MRI are the routine screenings done by health professionals to ascertain the categorization and prognosis of brain tumors but several circulatory biomarkers have emerged in the recent findings which can detect different forms of Brain and central nervous system tumors some of which have been discussed in the Table 1.(A) below

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Types of Cancer** | **Diagnostic Biomarkers** | **Prognostic Biomarkers** | **Predictive Biomarkers** | **Reference** |
| **Brain and Nervous system Cancers:**  Meningioma | Caspase-3(+), CD69(+) Prolactin(+), EGF(+), CCL24(+), Amphiregulin (+), HB-EGF(+), VEGFD (-) ,TGF-α (-), E-selectin *(-), BAFF (-), IL-12(-), CCL9(-)* Mutations in genes such as *NF2 ,TRAF7 (in Non-NF2* Tumors*), KLF4,ATK1, SMO*  *CHEK1, CLH22, SMARCE1*  *SMARCB, BAP1, CHEK2 , CHL22, PLOR2A* | *SERPINA1(+), CP(+), HPX (+), APOA1(+),*  *ALB(+), C3(+), A1BG(+), HP(+) and APCS(+),* | *Mutations in gene such as NF2 , PD-L1, AKT1 mutation, PIK3CA mutation, VEGF,PDF,EGF* | (Erkan *et.al*. 2019),(Roesler, Souza, and Isolan 2021),(Abbritti *et.al.* 2016), (Pawloski *et.al*. 2021) |
| Astrocytoma | GFAPδ *(+),* GFAPκ*, RNU6(+), MiR-320, MiR-574-3p,KPAN2* | *KPNA2* | Mutations in Gene *BRAF-KIAA1549,BRAFV600E,IDH1,IDH2,TP53,ATRX,H3F3A,K27M,H3F3A G34R/V,EGFR,FGFR2,PDGFRA,NF1,CDKN2A,PTEN* | (Bodegraven *et. al.,* 2019),  (Manterola *et.al.,* 2014),  (Gousias *et.al.,* 2012), (Sarhadi and Armengol 2022) |
| Craniopharyngioma | MMP-2,MMP-9, TrkA , β-catenin, Cyclin *D1* | MMPS, AnxA2(+),Cyclin D1(+), Ki-67(+).CXCL12(+) and CXCR4(+*)* | Mutationin *BRAF V600E,*Down regulation *in APC, ITGA, MCAM, and TIMP4* andup regulation *in CST7, CTSK, CTSL1, CXCL12, CXCR4, FN1, FXYD5, ITGB 3, MMP2, MMP3, MMP7, MMP9, NR4A3, PLAUR, TIMP2, and VEGFA* | (Smith *et.al.,* 2007; Y. Wang *et.al.,* 2017), (C. Xu *et.al.,* 2022),(Gong *et.al.,* 2014) |
| Ependyoma | H3K27me3, ZFTA-RELA fusion status, Ki-67 high labeling index and L1CAM positivity | *CDKN2A/2B loss ,*chr1q loss and chr1q25 gain | C11orf95–RELA fusion protein ,YAP1 gene fusions*, NF2 mutation****,****11q* aberrations *and* 22q deletion | (Chapman *et.al.,* 2023), (K. Y. Lim *et.al.,* 2022), (Bonnin 2019) |
| GBM | *EGFR mutation/ amplification ,MGMT promoter methylation IDH1/IDH2 mutation,circSMARC5(dysregulation)* | *MGMT(+),EGFR(+),PDGFRA(+),IDH(+),LOH10q,TP53(+),CTC(+),circHIPK3* | *miR-21(+),miR-10b(+),*  *miR-15b(+),miR-137(-),*  *miR-18d(-)* | (Sasmita, Wong, and Ling, n.d.) , (Szopa *et.al.,* n.d.) |
| Oligodendroglioma | *9pLOH and/or deletion of the CDKN2A gene,PIK3CA mutations,* | *1p/19q codeletion with IDH mutation(better prognosis), TERT mutation with 1p/19q codeletion (+ve prognosis), CIC+IDH mutation* (+ve prognosis*), Polysomy of 1p19q(-*ve prognosis*), TERT mutations with 1p/19q codeletion* (+ve prognosis*), TERTmutation without 1p/19q codeletion (-ve prognosis)* | *MGMT promoter methylation* | (Wesseling, Van Den Bent, and Perry 2015) |
| Pituitary Neuroendocrine Tumors | *H19,miR-143-5p,miR-423-5p,miR-21-5p,GNAS, USP8,USP48, HHIPL1,NNAT,RHOU,C5orf66 and RASSF* | *phosphorylation of serine 522 residue in correlates both with recurrence and invasion of NF-PitNETs, sst5TMD4 acts as a positive prognostic factor* | *SSTR2A,p-AKT (Ser743) or p-S6 (Ser240/244) expression levels, MAPK ,RKIP,Low β-arrestin mRNA expression,ZAC1 upregulation* | (Gossing, Frohme, and Radke 2020), (Barriuso *et.al.,* 2018),(Rai *et.al.,* 2022) |
| Vestibular schawnnoma | VEGF(+),bFGF(+), ErbB family proteins(+), CPI-17–MYPT(*+), NF-κβ,COX-2(+), High NLR,miR-29abc(+), miR-19(+), miR-340-5p(+), miR-21(+),miR-744(-), let-7b(-),MMP-2 and MMP-9,ADAM9(+), proteins like* ABCA3, SCG1, KLF11, CA2D1, BASP1and PRDX2 | *MMP-14(+)* indicates poor prognosis,*ki-67(+)* increased recurrence of Vestibular schwannoma | VEGF(-),PDGFR(-) | (Zhang *et.al.,* 2021), (Ren *et.al.,* 2020). |
| Chordoma | *Brachyury, SOX-9, CD24, Podoplanin, AE1/AE3* | *PD-L1(+), survivin(+), CDKN2A(* mutation*), CDK-12, i*nactivation *of SMARCB1,* D-dimer *(+)* and RDW *(+)* | *PD-L1,CDK2NA(*mutation), | (Rubino et al. 2022), (Barresi *et.al.,* 2014), (Oakley, Fuhrer, and Seethala 2008) |
| Primitive neuroectodermal tumor | CD99*,* translocations involving the *EWSR1* gene which is fused to an *E26* transformation-specific (*ETS) family gene (FLI-1, ERG, or ETS variant 1 (ETV1),* | *EWSR1* translocation, *CDKN2A(deletions) TP53,* | CD99*, EWS-FLI1 fusion gene, IGF-1R, PARP1* | (Louati *et.al.,* 2018), (Shukla 2013) |
| Germinoma | *HESRG, OCT4, PLAP, c-kit/CD117, NANOG, TFAP2c* | *miR-302/367, c-KIT /CD117, TP53, p53(+), ki67 (high proliferation index)* | *c-kit/CD117, miR-371a-373p, TP53-MDM2 signaling pathway,* | (Hattab *et.al.,* 2005), (Woo *et.al.,* 2017), (Takami and Ichimura 2022; Ostertag *et.al.,* 1987). |
| Hemangioblastoma | *VEGF(+),VHL gene mutation on chromosome 3,* | *VHL mutations* | *VEGF\*,VHL mutations \** | (Sundblom *et.al.,* 2022), (Gossage and Eisen 2010) |
| Pineoblastoma | *MYCN(+),* somatic mutationin *DICER1* | *OLIG2(+), somatic mutation in in ARID1A, KDM5C* | *MYC amplification,*TRK fusion *(role still unclear)* | (Z. Xu *et.al.,* 2022). (Kees *et.al.*, 1998; Pratt, Sahm, and Aldape 2021), (Raleigh *et.al.,* 2017; Laetsch *et.al.,* 2018) |
| Medulloblastoma | *miR-449a(-), OTX-2, Myc-amplification* | *WNT, SHH, Mutation on TP53 gene* | *WNT,SHH,Mutation on TP53 gene, chromosome7gain, chromosome 8 loss, and chromosome 11 loss* | (Y. Li *et.al.,* 2016),  (Lu *et.al.,* n.d.), (Goschzik *et.al.,* 2018) |
| Glioma | TP53, PTEN, CDKN2A, EGFR(+), IDH1, IDH2 mutation, | IDH1, IDH2 mutation, p53Mutation. 1p/19qcodeletion,  PTEN deletion, *ATRX mutation* | IDH1,IDH2 mutation, *BRAF (V600E) mutations,* *EGFRvIII, MGMT promoter methylation* | (H. Yan *et.al.,* 2009), (Schindler *et.al.,* 2011), (Jiao *et.al.,* 2012; Montano *et.al.,* 2011) |

1.2 **Cancers of Respiratory Tract**: Cancers of respiratory tract mainly includes cancers of lungs, larynx (2.76 cases per 100,000 people per year) Nasopharyngeal cancer (2.12 per 100,000 people per year)and other less common cancers such as tracheal cancer(0.1 per 100,000 people per year) (Nocini *et.al.,* 2020; Hao Yu *et.al.,* 2022; Arul V. Chandran3., n.d.) . Lung cancer remains one of the most deadliest and diagnosed cancers worldwide accounting 11.4% of all the cancer cases worldwide though it has been surpassed by Breast cancer in the recent years (Sung *et.al.,* 2021). Detection of respiratory cancers particularly lung cancers involve a wide range of techniques which includes Imaging Techniques( Chest X-Ray, PET scan, CT-scan),biopsy ,Genomic and proteomic analysis as well as Biomarker detection some of which have been discussed in the Table .1(B) below:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Types of Cancer** | **Diagnostic Biomarkers** | **Prognostic Biomarkers** | **Predictive Biomarkers** | **Reference** |
| **Cancers of Respiratory Tract:**  Lung cancer | ccCK18(+) *and total* CK18(+), *Cyfra 21.1,* EGFR9 (mutation), ALK *rearrangement,* *p40,CD56 ,chromogranin, synaptophysin,* KRAS (mutation) with TP-53(co-mutation), BRAF mutation, *EGFR mutation and amplification,* *miR-21, miR-214, miR-205, miR-92, miR-106, and miR-10a* | *CK18,* ROS1*fusions,*BRAF*mutations,*MET*amplifications,* KRAS(mutation) with TP-53(co-mutation),  *miR-21, miR-155* | EGFR9(mutation), ALK *rearrangement* KRAS(mutation) with TP-53 (co-mutation*,* *EGFR mutation and amplification* | (De Petris *et.al.,* 2011), (Affandi *et.al.,* 2018), (Kriegsmann *et.al.,* 2021), (Adderley, Blackhall, and Lindsay 2019; N. Yan *et.al.,* 2022), (Bethune *et.al.,*  2010), (Chalela *et.al.,* 2017), (Xue *et.al.,* 2016) |
| Laryngeal cancer | *p53 (+),CD1(+),*Ki-67 (high index value) | *VEGF(+), CD31(+), CD1(+), Ki-67(high index value),bcl-2(-) bcl-XL(-),* bax(+) | *CD1(+), TP53(mutation), bcl-2(-) bcl-XL(-),**HIF-1α C1772T polymorphism,* *ERCC1(-)* | (Schlüter et.al., 2018), (Cercelaru and Stepan 2017), (Zand *et.al.,* 2020), (Mittal and Bansal 2020; Nix *et.al.*, 2005), (Folic *et.al.,* 2022; Y. Hasegawa et al. 2017) |
| Nasopharyngeal carcinoma | *EBNA1,LMP1,*  *LMP 2,* *EBV VCA-IgA and EA-IgA , CK18(+),lncRNA*H19(+),MIR3936HG(+) | *MiR-29c-3p(-), Bmi-1,* | *plasma load of Epstein-Barr viral (EBV) DNA,* *PD-L1* | (Su et al. 2023; X.-M. Li *et.al.* 2009), (S. Wang, Claret, and Wu 2019), (Song *et.al.,* 2006; Hsu *et.al.,* 2017) |

\****Tracheal carcinoma: No such molecular diagnostic, prognostic and predictive biomarkers are available for tracheal carcinoma. Diagnosis is mainly based on clinical symptoms and examination along with bronchos copy and imaging techniques.***

1.**3 Gastro-intestinal carcinoma**: Gastrointestinal carcinoma encompasses a wide range of malignancies that affect various parts of digestive system which includes Colorectal cancers( 10.2%) , Gastric carcinoma (5.7%), Liver cancers(4.7%), Esophageal cancers(3.2%) , pancreatic cancer(2.5%) and relatively rare group includes GIST(Gastrointstinal stromal tumors), Biliary tract cancer and Neuroendocrine tumors(Arnold et al. 2020).Though imaging techniques along with physical examination forms a major part of diagnosis many potential biomarkers have been studied for GI tract carcinomas some of which has been discussed below in the table 1C:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of cancer** | **Diagnostic Biomarker** | **Prognostic Biomarker** | **Predictive Biomarker** | **Refereences** |
| **Gastro Intestinal cancers**  Colorectal Cancer | *CEA, IL-10 (+), IL-17A(+), TGF-β(+), TNF-α(+)* | *CEA.*BRAF (mutation),KRAS,TP53, 18q alteration | BRAF (mutation), *KRAS* (mutation), *NRAS (mutation), BRAFV600 mutation, HER2(+)* | (Ma et al. 2022),(Nakayama, Hirota, and Shinozaki 2020),(Pino and Chung 2010; Custodio and Feliu 2013),(Ivanova et al. 2022) |
| Gastric Cancer | *CA72-4, GKN1(-),*  *TFF3(+), Helicobacter pylori*  *Antibodies(+)* | *miR-21,miR-145,miR-184, miR-20b, miR-9-1, miR-9-2, miR-1537, miR-549,miR-802,  HER2,* *Ki-67,* *VEGF,* *E-cadherin* | *Ki-67,HER2(+),*  *MET amplification,*  *MET(+), VEGF-A, Low mRNA expression of EGFR/FGFR2/MYC* | (M. Li et al. 2020),(Yoon et al. 2019),(Yuan, Wang, and Zhang 2018),(Ko et al. 2017),(Xiong et al. 2019),(D.-H. Liu 2001),(Kim and Green 2014)  , |
| Liver cancer | *AFP(+), AFP-L3%(+),* *DCP(+), GPC3(+), OPN(+)* | *GPC3, AFP,AFP-L3% CTNNB1* | *PDGFR, VEGF-R, KIT, FGFR1,* *FGF19/FGFR4,* *PD-L1* | (F. Zhou et al. 2018),(De et al. 2016),(Abdel-Hafiz et al. 2018),(L. Chen et al. 2021),(Gao et al. 2017),(Brunetti et al. 2019),(X. Zhou et al. 2023) |
| Esophageal carcinoma | *p53 antibody CEA, SCC, CYFRA211, CDC25B-Antibodies, miR-129* | *CYFRA 21–1 , SCC-Ag,* *NSE,* *HER2* | BRCA1*/2 (mutation),* *HER(amplification)* | (Yin and Liu 2020),(Ju et al. 2022),(Iqbal and Iqbal 2014), (Tan et al. 2016),(Zimmer et al. 2021),(Plum et al. 2019) |
| Pancreatic carcinoma | *CA19-9(+), VEGF,FGF-10/KGF-2,Tgf-β,* *CA125.* *Osteonectin(+),Laminin* ***γ****2(+), Soluble CD40 ligand,* ***C4b-binding protein a-chain,***  *REG1β.* *SYCN(+), GPNMB,*  *MMP-7,* *MMP-12* | *Laminin****γ****2,UL16 binding protein 2,* *Soluble CD40 ligand,* *VEGF-A,* *ICAM-1* | *CXCL11.* *CEACAM1,BRCA1/2(mutation),* *KRAS(mutation)PD-L1,* | (O’Neill and Stoita 2021),(Amaral et al. 2023),(Hu et al. 2019) |
| GIST | *DOG1, Ki-67, SDH(-), PKC theta,* *PDGFRA* | *Ki-67,* *KIT(mutation),* *CDH1(methylation),* *SETD2,* *SLIT and NTRK,* *ROR2* | *SDH(promoter hypermethylation),* *BRAF(mutation at exon 15), PDGFRA (mutations), SDH,*  *BRAFV600* | (Sözütek et al. 2014),(De Silva et al. 2021),(Motegi et al. 2005),(X. Liu and Chu 2019),(Incorvaia et al. 2021),(Huss et al. 2017) |
| Biliary Tract cancer | *CA19-9(+), CA125.(+), AFP(+), MUC1(+),*  *IDH1 or IDH2 mutataion* | *CA19-9(+), CYFRA 21-1(+), MMP-7(+), suPAR,*, AGR ratio, *miR-150(+), NKG2D(+),*  *CD55(+), CD97(+)* | *IDH1 or IDH2 mutataion,* *FGFR2(+), VEGFR2,* *HER2/neu(+)* | (Chaube et al. 2006),(Tao et al. 2010),(S. Y. Park et al. 2009),(Sumbly, Landry, and Rizzo 2022),(Pavicevic et al. 2022) |

1.4 **Hematological Malignancies**: A hematological malignancy includes a variety of diseases that arise from bone marrow. Malignancies encompass leukemia’s, lymphomas, and multiple myeloma. Each of them has an unique pathophysiology, clinical presentation and therapeutic approaches .Molecular diagnostics has a wide application in the field of Hematology and hematopathology which help in guiding diagnosis, sub-classification, prognosis and outcomes of therapeutic intervention.-Biomarkers involved in hematological malignancies include chromosomal translocations such as t(9;22) (BCR-ABL1)fusion in Leukemia and MYC, BCL2, and BCL6 Translocations in lymphomas. Few biomarkers are discussed below in the table 1.D

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Type of Cancer | Diagnostic | Prognostic | Predictive | Reference |
| **Hematological Malignancies:**  Leukemia | t(8;21)(AML), t(15;17)(AML), inversion 16(AML), trisomy8 (AML), BCR-ABL fusion protein (CML)) | Mutation in *CEBPA,* *DNMT3A, IDH1/2,*  *TET2(*AML*),WT1(*AML*), ERG* expression *(*AML*), BAALC (*AML*)* expression, *FLT3-ITD* Mutation (AML) NOB1(CML), DDX47(CML), IGSF2(CML), LTB4R(CML), SCARB1(CML), and SLC25A3(CM) | *FLT3* (AML), *NPM* (AML), *CEBP* (AML), SAMHD1 (AML),  *HMGCLL1(CM),* BCR-ABL kinase | (Hussaini 2015; Kiyoi, Kawashima, and Ishikawa 2020), (Schneider et al. 2017), (Prada-Arismendy, Arroyave, and Röthlisberger 2017), (J.-H. Park et al. 2019) |
| Lymphoma | *BCL6,Myc (Burkitt lymphoma), MYD88L265P (mutation), CIITA translocation (HL), ID3 and MYC, TPST2 and RE mutation (BL),  CD30(HL), Bcl-6(TCL), SOX-11 (MCL),* | *BCL6(+),*TP53 mutation (BCL), MYD88 (L-BCL), Bcl-6(TCL), p53 | TP53 mutation (BCL), *MYC-IG transloacation,* LMO2 (BCL)*, BCL6 (BCL), FN1 (*BCL*), CCND2 (*BCL*), SCYA39 (*BCL*),* | (Sun, Medeiros, and Young 2016) |
| Multiple Myeloma | t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies, and del (17p), M protein, VEGF (+), HGF(+), angiopoietins (+) and *JunB(+), miR-15a (-) miR-16a (-), miR-17(+),miR-19b (-), miR-25 (-)* | M protein level, β2-microglobulin levels, FGF-2, | VEGF(+), HGF(+), angiopoietins (+) and JunB (+) (HIF)-2α (+) | (Soliman, Das, and Teoh 2021; Rajkumar 2020) |

**1.5 Gynecologic Malignancies**: Most common malignancies of the female reproductive system include Ovarian, endometrial, and cervical cancers. The most common gyenologic cancers affecting women worldwide are Ovarian and cervical cancers. Although Cervical cancer is declining in number and trend, but still remains the second most common cancer in women after breast cancer, which is till now the most deadly and frequent cancer worldwide (<https://www.who.int/news-room/fact-sheets/detail/cancer>). In India every single year, 122,844 women are diagnosed on an average with cervical cancer and 67,477 die for the same(Maheshwari, Kumar, and Mahantshetty 2016). Intermediate in frequency between cervical cancer and endometrial cancers, but till now reported as the most fatal, is ovarian cancer which killed about 15000 women out of 20000 diagnosed in US(Ueda et al. 2010).Hence, in case of endometrial, ovarian and cervical cancers, it is difficult to detect the disease at preliminary stage. In this section (Table 1.E) we discuss about few of the biomarkers which are already in use along with few novel Biomarkers for future which helps in better detection, prognosis and management of gynecologic cancers, including endometrial, ovarian and cervical cancers.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of cancer** | **Diagnostic Biomarker** | **Prognostic Biomarker** | **Predictive Biomarker** | **Reference** |
| **Gynecologic Malignancies:**  Ovarian Cancer | CA 125(+),CA 19-9(+), HE4(+,),ApoA-1(+),IGFII, MIF, *BRCA1 and BRCA2, PTEN, CDH1* | CA125, KLKs, OPN, ALDH1 | VEGF, Mesothelin, lncRNA and mRNA, GSTP, FOLR1, *BRCA1 and BRCA2* | (Ueda et al. 2010; Atallah et al. 2021) |
| Endometrial Cancer | CA125(+),HE4(+)ApoA-1(+).CA 72-4(+),CEA(+),*MLH1, MSH2, MSH6, PMS2, and EPCAM*. | CA 15-3,E3, E1-S. NLR,MLR,PLR,SII etc | EGFR tyrosine kinases, PTEN, PI3K, Bcl-2, p53 | (Ueda et al. 2010),(Njoku, Barr, and Crosbie 2022; Banno et al. 2012) |
| Cervical Cancer | SCC(+),CYFRA 21-1(+),CA 125(+),CA 19-9(+),IAP(+),CEA(+),YKL-40(+) | CYFRA 21-1,IAP, CAIX, GLUT1 | GLUT1, CAIX, HKI | (Ueda et al. 2010; Moreno-Acosta et al. 2016) |
| Breast Cancer | TFF1, TFF2, TFF3, CEA, CA 15–3, *miR-21, miR-1246, miR-155, miR-29a, miR-146a, miR-373, miR589, miR-221/222 cluster, miR-9, miR10b, miR-96, miR-181, miR-375, and miR-520c,* HER2, Ki67, *BRCA1 and BRCA2, PTEN, CDH1* | CA 15–3, *miR-155*, c-erbB-2, TGF-α, EGFr, bcl-2 | *, miR-1246, miR-155, miR-29a, miR-146a, miR-373, miR589, miR-221/222 cluster, miR-9, miR10b, miR-96, miR-181, miR-375, and miR-520c,* *miR-7,* *Axis of RNA/miR-7-*5p/Raf1, TRAF4, Erα36, HER2, Ki67, *BRCA1 and BRCA2* | (Afzal et al. 2022; Beenken et al. 2001) |

***\*We have grouped breast cancer as a part of gynecologic cancer as they come under the umbrella of "women's cancers" due to their predominant occurrence in females and also to highlight the importance of breast cancer and the novel a wide range of biomarkers associated with it however they are generally classified differently based on the anatomical origin and their clinical management\****

2. **Cardiomyopathy Biomarkers**: Cardiomyopathy is disease of heart muscle which makes the heart work harder to pump blood to the rest of body. Cardiomyopathy can lead to heart failure. The type of cardiomyopathies include 1) Hypertrophic cardiomyopathy (1:250/500) 2) Dilated Cardiomyopathy (1:250/500) 3) [Arrhythmogenic cardiomyopathy](https://www.nhlbi.nih.gov/health/cardiomyopathy/types#Arrhythmogenic-cardiomyopathy) (1:250/5000)4) Restrictive Cardiomyopathy (uncommon) (McKenna, Maron, and Thiene 2017).

**2.1 Hypertrophic cardiomyopathy:** Hypertrophic cardiomyopathy (HCM) is a hereditary condition distinguished by the thickening of the left ventricular wall, unexplained by other hemodynamic stress factors. At a microscopic level, it showcases a pattern of disordered heart muscle cells, fibrosis, and irregularities in the tiny blood vessels within the heart muscle. HCM is singular in nature, being a monogenic heart ailment, and is typically inherited in an autosomal dominant manner with varying degrees of expression. In the broader population, its prevalence stands at about 1 in every 500 individuals (Cambronero et al. 2008) .The most promising field where biomarkers have played essential role in cardiomyopathies are ischaemic heart disease and heart failure. Various biomarkers have shed light on the pathophysiology of atheromatous plaque, as explored in Cambronero et al. 2008. Specific biomarkers like B-type Natriuretic Peptide and N-terminal pro b-type Natriuretic Peptide are of interest because their levels elevate in reaction to stress on the myocardial wall. Additionally, high-sensitivity Troponins, as well as indicators of myocardial fibrosis such as Galectin-3 (Gal-3), play crucial roles. Moreover, markers reflecting collagen turnover, like PICP (C-terminal propeptide of procollagen type I) and PIIINP (N-terminal propeptide of procollagen type III), are also pivotal in understanding cardiac pathologies. Elevated levels of which reflect the increased collagen turnover seen in the myocardial fibrosis of HCM.

**2.2 Dialated Cardiomyopathy:** Dialated cardiomyopathy (DCM) is a cardiac muscle disorder characterized by ventricular chamber enlargement and systolic dysfunction with normal ventricular wall thickness. The etiologies of DCM are diverse and ranges from genetic mutations to post viral response. Though a considerable amount of progress has been made in recent years DCM continues to be an important reason behind cardiac transplant. Several biomarkers for example C-reactive protein (*CRP*), Galectin 3( *Gal-3*), B-Type Natriuretic Peptide (*BNP*) and N-Terminal-pro Hormone BNP (*NT-proBNP*) have emerged which proved to be of great deal of importance in diagnostic, prognostic and management utility in DCM(Anghel et al. 2021).

**2.3** [**Arrhythmogenic cardiomyopathy**](https://www.nhlbi.nih.gov/health/cardiomyopathy/types#Arrhythmogenic-cardiomyopathy): Arrhythmogenic cardiomyopathy (AC), also referred to as arrhythmogenic right ventricular dysplasia, is a comparatively rare genetic disorder of the heart muscle. This condition is marked by fibrofatty substitutions in the myocardium and is linked with ventricular arrhythmias. While AC predominantly impacts the heart's right ventricle, it can also manifest in the left ventricle. Biventricular involvement in AC may progress to heart failure, as noted by Akdis et al. 2022. Recent breakthroughs in genetic testing have pinpointed non-desmosomal gene mutations, which are often linked to biventricular (BiV) and left ventricular (LV) dominant forms of ARVC, as stated in Akdis et al. 2022. Established diagnostic and prognostic biomarkers for this condition include the Brain-derived natriuretic peptide (BNP) and its N-terminal variant (NT-pro BNP). Recently, newer biomarkers have been identified, such as the soluble suppression of tumorigenicity-2 (sST2), galectin-3 (Gal-3), and growth differentiation factor-15 (GDF-15).

**2**.4 **Restrictive Cardiomyopathy :** Restrictive cardiomyopathy (RCM) is a cardiac muscle disorder which is characterized by dystolic dysfunction of non-dialated Ventricle .The major reasons behind Restrictive Cardiomyopathy are Cardiac amylodoisis, cardiac sarcodiasis and cardiac hemachromatosis. ECG (Electro cardiogram )is one of the first tools used in diagnosis along with CMR (Cardiac magnetic resonance).Certain biomarkers have emerged as important diagnostic and prognostic tool such as troponin T, B-type natriuretic peptide (BNP), and pro-BNP(Rene R. Diaz4. and Kristen N. Brown1, n.d.)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Types of Cardiomyopathies** | **Diagnostic Biomarker** | **Prognostic Biomarker** | **Predictive Biomarker** | **Reference** |
| Hypertrophic cardiomyopathy | IL-6(+), TNF-a(+), ANP(+), BNP(+), s-Fas(+),sTNFRI(+), CRP(+),Endothelin-1(+),PICP(+), | *MYBPC3 variants,* *MMP, TIMP,* Gal-3*,* Cardiotrophin | BNP and NT-proBNP *LYVE1(-), MAFB(-), and MT1M(-)* | (Zen et al. 2005),(Penicka et al. 2001),(Dimitrow et al. 2008), (Fassbach and Schwartzkopff 2005),(K. Hasegawa et al. 1996, 1),(Masson 2006; Jansen et al. 2021; Matthia et al. 2022) |
| Dialated Cardiomyopathy | *CRP(+),NLR ratio, Gal-3(+),*Chemerin(+),TNF-α, BNP(+),N-Terminal-pro Hormone BNP(+), ST2(+),H-FABP(+)s MMP-1, MMP-9, T-cadherin(+) | CRP(+), IL-6 (+) (TNF)-α(+),ST2(+)Syndecan-1(+),GDF-15(+),Syndecan-4 | BNP and NT-proBNP, MD-2 | (Anghel et al. 2021; Masson 2006; Riad et al. 2018) |
| Arrhythmogenic cardiomyopathy | NT-pro BNP(+), BNP(+),BIN1(+) | sST2(+), l-3(+) and GDF-15(+),BIN1(+),connexin-43*, miR-130a(+)* | BNP and NT-proBNP | (Akdis et al. 2022; Masson 2006; Alcalde et al. 2023) |
| Restrictive Cardiomyopathy | NP(+),BNP(+),NT-pro BNP(+*)*,*TNNT2 TNNI3.* | *Galectin-3(Gal 3), TNNT2,TNNI3* | BNP and NT-proBNP, amyloid load, | (Andrew Connelly, n.d.), (Hara et al. 2020), (Masson 2006) |

**3. Autoimmunity Biomarkers:** A diverse range of autoimmune and rheumatic diseases exist, wherein the immune system erroneously attacks the body's own tissues. These disorders target different organs and systems, such as Multiple sclerosis (MS): Primarily affects the brain, Rheumatoid arthritis (RA): Predominantly targets the joints, Type 1 diabetes (T1D): Primarily involves the pancreas, Sjogren’s syndrome (SS): Chiefly affects the salivary glands, Celiac disease: Predominantly impacts the small intestine, Systemic lupus erythematosus (SLE): Can affect nearly every organ and system within the body.

Each of these conditions demonstrates how the immune system, instead of protecting the body, can sometimes turn against it, leading to a myriad of symptoms and complications (Fenton and Pedersen 2023; Singh et al. 2019). Production of autoantibodies, activation of immune cells, increased expression of pro-inflammatory cytokines, and activation of type I interferons are signature of Autoimmune disorders. Though improvements have been made in treatments and Diagnostic tools the time taken for the patients to be diagnosed is quite lengthy and the procedure it involves is too long to bare with the main treatment for these disease still relies on non-specific anti-inflammatory drugs. Biomarkers play a pivotal role in the diagnosis, prognosis, and prediction of therapeutic response in autoimmune diseases cutting short the long procedure involved previously. Biomarkers generally involve circulatory macromolecules in serum and also genetic variations linked with prediction of autoimmune disorders. Though there are more than 80 types of autoimmune diseases (<https://medlineplus.gov/autoimmunediseases.html#:~:text=There%20are%20more%20than%2080,Autoimmune%20hepatitis%20affects%20the%20liver>.) We will discuss about few notable autoimmune diseases and the biomarkers associated with it in the table 3A given below:

**3.1 Multiple sclerosis:** Multiple sclerosis (MS) is a long-term, immune-mediated disease characterized by inflammation and the loss of the protective myelin sheath around nerve fibers in the central nervous system (CNS). This disease typically manifests in individuals aged between 20 and 40 years. Relapsing-remitting multiple sclerosis (RRMS), the most prevalent subtype of MS, is marked by episodes of symptom exacerbation followed by periods of recovery. Numerous treatment modalities currently exist to decrease the frequency of relapses and control neuroinflammation in RRMS patientsbut still it is crucial to find a specific and sensitive biomarker which will provide essential clinical readout based on both diagnosis and prognosis for example : Recent development of sensitive assays has identified Nfl (Neurofilament light chain) as potemtial biomarker but Nfl didnt emerge as the only biomarker in the assay as there's a notable similarity in the range of serum NfL (sNfL) levels in individuals with MS when compared to healthy controls. Consequently, both blood and cerebrospinal fluid (CSF) biomarkers indicating axonal injury, neuronal damage, glial dysfunction, demyelination, and inflammation have been thoroughly researched as potential actionable biomarkers for MS (Yang et al. 2022).

**3.2** **Rheumatoid arthritis (RA):** Rheumatoid arthritis (RA) is a pervasive chronic inflammatory condition that, if left undiagnosed or improperly managed, can lead to joint deformities and functional limitations. Recognizing and treating RA promptly is essential for effective management, increasing the likelihood of remission, and averting lasting clinical and radiographic harm. In clinical settings, rheumatologists often employ a scoring system formulated by the American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) to validate the diagnosis of Rheumatoid arthritis (Chaube et al. 2006). Few novel biomarkers are now being available for routine clinical use this includes rheumatoid factor, C-reactive protein and erythrocyte sedimentation rate for diagnosis and prognosis of Rheumatoid arthritis.

**3.3 Type 1 diabetes (T1D)**. Type 1 diabetes (T1D) is a chronic autoimmune condition marked by a lack of insulin due to the autoimmune-mediated obliteration of insulin-producing pancreatic β-cells found in the islets of Langerhans. While lifelong insulin administration remains a standard approach for managing glucose levels in T1D patients, no definitive curative treatments are currently available for this ailment .Biomarkers play a pivitol role in the diagnosis, prognosis, and potential prediction of therapeutic responses or disease progression in T1D. While the development of specific blood serum (or plasma) biomarkers holds considerable appeal, crafting such serum markers, especially those indicating pancreatic β-cell death or stress, has proven to be a formidable challenge in the context of T1D. Until now the biomarkers implemented mainly include glucose, HbAlc, c-peptide, and autoantibodies (AAb) for clinical practice(Yi, Swensen, and Qian 2018).

**3.4 Sjogren’s syndrome** :Sjögren's syndrome is a persistent systemic inflammatory autoimmune condition marked by keratoconjunctivitis and xerostomia. Beyond the primary glandular symptoms, the disease's manifestations extend to include synovitis, interstitial lung disease, neuropathy, renal disease, vasculitis, and autoimmune cytopenias. Alarmingly, patients diagnosed with Sjögren's syndrome exhibit a 6.5-fold elevated risk of developing non-Hodgkin’s lymphoma, a risk surge that surpasses that associated with any other autoimmune ailment(W. Chen et al. 2015). The disease can be primary (without any associated autoimmune disease) or secondary (in association with another autoimmune disease, such as rheumatoid arthritis or systemic lupus. Diagnosis mainly occurs through labial salivary gland biopsy and is often helpful to diagnose the pSS disease according to revised 2002 American-European criteria(W. Chen et al. 2015). As biopsy involves an invasive procedure hence noninvasive biomarkers are needed for the diagnosis and prognosis of Sjogren' syndrome which includes Carbonic Anhydrase-1 (CA-I) and cytokines such as IL-4 and IL-5.

**3.5 Celiac Disease**: Celiac disease is a systemic autoimmune condition triggered by the consumption of gluten, a protein present in wheat, barley, and rye, resulting in damage to the small intestine. Previously perceived as a rarity, celiac disease has emerged as one of the more prevalent conditions worldwide. The primary therapeutic approach involves abstaining from gluten or maintaining a gluten-free diet. Currently, there isn't a definitive gold standard test for its diagnosis. Instead, identification largely relies on presenting physical symptoms, detection of a celiac-specific antibody (like anti-tissue transglutaminase antibody, anti-endomysial antibody, or anti-deamidated gliadin peptide antibody), and the observation of villous abnormalities in the small intestine.Enteropathy is one of the significant hallmark complication of celiac disease which can only be investigated by endoscopic examination which is perceived as invasive hence this lead to development and identification of novel non invasive biomarkers which has a definite role in diagnosis of the disease such as Anti-gliadin antibody(AGA) Anti-endomysial antibody (AEA)(Singh et al. 2019).

**3.6 Systemic Lupus erythematosus** : Systemic lupus erythematosus (SLE) is multisystemic autoimmune disease with a complicated etiology and is characterized by peculiar activity of the immune system.(Haitao Yu, Nagafuchi, and Fujio 2021) A wide range of Clinical symptoms are manifested by SLE including renal, dermatological, neuropsychiatric, and cardiovascular symptoms. A multidisciplinary approach should be manifested to treat SLE in terms of controlling the symptoms and delay the progression of the disease. Biomarkers, especially immunological biomarkers, have emerged to aid in better diagnosis of SLE and determine its pathophysiological processes. For example- Antinuclear Antibodies (*ANA*) and urinary markers like MCP-1 (Monocyte Chemoattractant Protein-1), and TWEAK (Tumor Necrosis Factor-like Weak Inducer of Apoptosis) can provide information on renal disease status and prognosis.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of Autoimmune Diseases** | **Diagnostic Biomarker** | **Prognostic Biomarker** | **Predictive biomarker** | **Reference** |
| Multiple sclerosis | cNfL(+), SNfl(+),  APP(+), TUB*β(+),* NSE(-), AQP4(-), MOG(+) | cNfL(+), tau (+),  GFAP, S100β(+) | cNfL(+), CHI3L1(+),  HSP70(+), HSP90(+) | (Yang *et.al.,* 2022) |
| Rheumatoid arthritis | RF(+), anti-CCP2(+), anti-MCV, serum-14-3-3eta, anti-CarP, | DAS28-CRP, SDAI, DAS28-ESR, IL-6, serum VEGF, serum COMP,CTX-I, CTX-II, MMP-1 and MMP-3 | anti-CCP2(+) | (Shapiro 2021) |
| Type 1 Diabetes | C-peptide(-), ICA,GADA,IA-2A, ZNT8A,ADIPOQ, APOA4, APOC4, AZGP1, BTD, KNG1, LUM, SERPINA6 | C-Peptide, HbA1c | ICA, GADA, IA-2A, ZNT8A | (Yi, Swensen, and Qian 2018) |
| Sjogren’s syndrome | Flt-3L(+), IL-4(+), IL-5(+), clausterin, cathepsin, CA-I(-), BAFF(+), RF(+), ANA(+), Anti-SSA (Ro) and Anti-SSB (La) antibodies | Flt-3L(+), CXCL13, C4, Polymorphisms in TNFSF13B and TNFRSF13C | MxA(-), IFN type I a, | (Brito-Zerón *et.al.,* 2016)**,** (W. Chen *et.al.,* 2015) |
| Celiac Disease | (AGA), (AEA),Anti-tissue transglutaminase (tTG)- TG2, TG6, TG3 (DGP), Synthetic neo-epitopes tTG-DGP comple | CYP3A4, Plasma citrulline, I-FABP, Reg 1α | HLA-DQ haplotyping | (Singh *et.al.,* 2019) |
| Systemic Lupus Erythematosus (SLE) | Serum ANA, C3(-), C4(-), ANA(+), ESR(+), CRP(-), antiC1qAb, Chemokines (CXCL-16,TGF-β, TWEAK,MCP-1, V-CAM, I-CAM | Anti-dsDNA antibodies, Paraxonase-1 and HDL, Serum anti-ds DNA Ab, serum Anti-Sm Ab, IL-10(+), IL-6(+), TNF-a(+), IFN-γ(+), MCP-1(+), IP-10(+) | Cardiac Troponin T | (Haitao Yu, Nagafuchi, and Fujio 2021) |

**4 Biomarkers in Infectious diseases** : Infectious diseases arise from the invasion of pathogenic microorganisms, including viruses, bacteria, parasites, and fungi. Globally, these diseases have exerted significant strain on health and economic infrastructures. In developing nations, notably India, research indicates that infectious diseases remain a persistent challenge, with over 33% of the country's afflicted population grappling with such ailments (Ram and Thakur 2022) . Among the myriad infectious diseases prevalent globally, HIV, tuberculosis, and malaria stand out for their significant contribution to global mortality rates. Additionally, numerous neglected tropical diseases, including Chagas disease, dengue, yellow fever, West Nile, Japanese encephalitis, and chikungunya, are recognized as formidable threats on the global health landscape(Hwang, Hwang, and Bueno 2018); about half of the world population face direct threat of developing fatal illness due to infectious diseases and hence early detection of such infections is estimated to significantly reduce the mortality rate. Hence discovering Highly sensitive and specific biomarkers for diagnosis and prognosis has really been a challenge as they can indicate the presence of an infection, the stage or severity of an infection, or the body's response to treatment For example: Adenosine deaminase (ADA) has been a major diagnostic marker for Tuberculosis (TB) on the other hand procalcitonin (PCT) assay, is used that can discriminate between a viral and a bacterial infection and has been approved by Food and Drug Administration(FDA). Biomarkers for few infectious diseases have been enlisted below.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Types of Infectious Diseases** | **Diagnostic Biomarker** | **Prognostic Biomarker** | **Predictive Biomarker** | **Reference** |
| **Viral infections:**  Influenza | Influenza viral RNA CRP (+), *PBI, MMP8, TCN1, RETN, OLFM4, ELANE, LTF, LCN2, DEFA4 and HP* | CRP, *BPI, MMP8,* *PBI, MMP8, TCN1, RETN, OLFM4, ELANE, LTF, LCN2, DEFA4 , HP,* D-dimer | IL-6, IL-10, and TNF-α | (Vasileva and Badawi 2019), (S. Liu *et.al.,* 2021), (Z. F. Wang *et.al.,* 2011), (To *et.al.,* 2010) |
| HIV | hs-CRP(+), IL-6(+), D-dimer (+), protein S (-), protein C (-), LPS(+), 16s DNA, sCD14 (+), IFN-γ (+), I-FABP, HLA-DR, CD38, Ki67, Caspase 3, sTNFR-1 | PPI,  p24 | d-Dimer, IL-6, | (Rubio Caballero *et.al.,* 1999; Nixon and Landay 2010) |
| Hepatitis | IgM anti-HBc, IgG anti-HBc, HBsAg, HBV DNA, | HBcrAg, M2BPGi | HBcrAg, | (Baudi, Inoue, and Tanaka 2020) |
| COVID-19: | CRP(+), ESR(+),  IL-6 (+), NSE, LDH, AST, CK-MB, myoglobin, D-dimer, BNP(+), NT-proBNP(+) | NSE, LDH,AST, Surfactant protein-D, angiopoietin-2, CRP, ferritin, Myoglobin, l ow HDL | D-dimer.,IL6, CRP levels | (Battaglini *et.al.,* 2022; Guaraldi *et.al.,* 2020), (F. Liu *et.al.,* 2020) |
| **Bacterial Infection:**  Tuberculosis | Ag85A(+), Ag85B(+), and Ag85C(+), Mtb DNA,LAM, IFNγ, IFNαβ, IP10(+), CD27(-), Ki-67, Mtb-specific CD4+ T-cell, Rv1733c, Rv2029c, Rv2628 and HBHA | plasma chitinase, IDO, Ag85A, interferon (IFN)-γ specific T-cells, | IP10(+),  VEGF, HO-1, MMPs, IL11 | (Kumar *et.al.,* 2023; Goletti *et.al.,* 2016; Petruccioli *et.al.,* 2016) |
| **Infection caused by protozoa:**  Malaria | PCT, var genes, CK-MB, CKD-EPI eGFR, pLDH, HMGB1, D-dimers, carboxyhemoglobin, *pfhrp2* | CRP, Ang-2, Ang-2/1 ratio, PfHRP2, VCAM-1, sICAM-1, TNF-α, vitronectin, IL-10, CXCL10, | *pfhrp2* | (Foko *et.al.,* 2022; Atroosh *et.al.,* 2022) |
| Dengue | NS1 antigen, IFN-γ, TNF-α, IL-1, IL-6, IL-8, IL-10, CCL2 (MCP-1) and CCL5 (RANTES), IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17, IL-18 , MIF and chemokines CCL2, CCL4, CCL5, and CXCL10 (IP-10) | Ang-1(-), ngptl3(+), sKDR(+), sEng(+), sICAM-1(+),CRP(+), CXCL10/IP-10(+), CHI3L1(+), C5a(+) , Factor D(+), CD95(+), IL-6(+), IL-10(+), IFN-γ(+), MIF(+), and CCL-4(+) | IL-6(+), IL-10(+), IFN-γ(+), MIF(+), and CCL-4(+) | (Alcon *et.al.,* 2002), (John, Lin, and Perng 2015; Conroy *et.al.,* 2015) |

**5. Neurodegenerative disease and Neuropsychiatry Biomarkers**

* 1. **Neurodegenerative disease:**

Neurodegenerative diseases are caused by rapid and consistent loss of selectively vulnerable neuron population. The process is contradictory to static neuronal loss as the later may get initiated due to any metabolic disorder or toxicity effect within a system. The clinical classifications of neurodegenerative diseases are broadly categorized as extra-pyramidal and pyramidal movement disorders and behavioral or cognitive disorders as the most common ones. In general neurodegenerative diseases are marked by specific protein accumulation and much anatomic vulnerability. Different particular neurodegenerative disease may show different effects in very fundamental processes of a living organism leading to neuronal dysfunction and death. The particular pathways that may lead to such effects can be proteotoxic stress, abnormalities in ubiquitin- proteasomal reactions, autophagosomal and lysosomal system dysfunctions, PCD (Programmed Cell Death), oxidative stress and neuro-inflammation. The detection of neurodegenerative diseases are a matter of big concern as the process becomes critical since the evidence of particular protein factor accumulation is subjected under question as it will be checked only after the onset of symptoms in a particular organism and not in its healthy state  ([Gibb and Lees 1988](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C53); [Sparks et al. 1994](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C131); [Schmitt et al. 2000](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C126); [Adler et al. 2010](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C2); [Evidente et al. 2011](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C45); [Frigerio et al. 2011](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C47); [Milenkovic and Kovacs 2013](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C107); [Dugger et al. 2014c](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495060/#A028035C41)). The other important factor making the disease diagnosis a difficult task is onset of more than one neurodegenerative diseases at the concurrent time in a particular individual (Uchikado et al. 2006a; Dugger et al. 2014a)

Most common types of neurodegenerative disorders are taupathies, TDP 43 (transactivation response DNA binding protein-43 proteinopathies, amyloidoses and α-syneucleinopathies. The following chart represents the type of most common neurodegenerative disorders-

|  |  |
| --- | --- |
| Type | Examples |
| Amyloidoses | Alzheimer’s disease, Familial British dementia, Gerstmann-Strӓussler-Scheinker disease etc. |
| TDP-43 proteinopathies | Progressive muscular atrophy, Amyotrophic lateral sclerosis, Frontotemporal lobar degeneration, Primary lateral sclerosis etc. |
| Taupathies | Chronic traumatic encephalopathy, Pick’s disease, corticobasal degeneration etc. |
| Synucleopathies | Multiple system atrophy, Lewy body disorders etc. |

(Reference: Dugger and Dickson, 2017)

All specific neuropathological diagnosis for neurodegenerative disorders are based on abnormal protein conformation and their accumulation. Some example of such protein accumulations are

|  |  |
| --- | --- |
| Disease | Protein accumulated |
| Pick’s disease | 3R tau |
| Progressive supranuclear palsy, Argyrophilic grain disease, corticobasal degeneration | 4R tau |
| Chronic traumatic encephalopathy, Primary age related taupathy, | 3R+4R tau |
| Alzheimer’s disease | Aβ, 3R+4R tau |
| Lewy body disorder, Multiple system atrophy | α – Synuclein |
| Primary lateral sclerosis, Frontotemporal lobar degeneration, Progressive muscular atrophy | TDP-43 |
| Familial British dementia | ABRI |
| Creutzfeldt-Jakob disease, Gerstmann-Strӓussler-Scheinker disease | PrP |

(Reference: Dugger and Dickson, 2017)

As the accumulation and conformational change of the aforesaid proteins are directly related to expression of neurodegenerative diseases, these are regarded as biological markers for the respective diseases.

* 1. **Neuropsychiatry disorders**

Some of the common Neuropsychiatric disorders are Palsies, Attention deficit disorders, Schizophrenia, Cognitive deficit disorder, Dementia etc. In these particular types of disorders both neurological and psychiatric sides are compromised in the effected individual. The effect of the disease affect both nervous system( brain especially), emotional sides and mood of a particular individual. A mechanistic interaction between nervous system and immune system of an individual leads to onset of such disorders. An exposure to different chemicals, mycotoxins, molds and other biological as well as environmental contaminations may lead to initiation of neuropsychiatric disorders (Empting, 2009). Classification of biological markers associated with neuropsychiatric diseases is elaborately described by Davis *et.al.*, 2014. Davis and his team has characterized the biomarkers of neuropsychiatric diseases broadly in six groups-

1. Biomarkers of risk
2. Biomarkers of diagnosis or trait
3. Biomarkers of acuity
4. Biomarkers of stage
5. Biomarkers of treatment response and
6. Biomarkers of prognosis
   * 1. **Biomarkers of risk:**

This type of biomarkers gives a quantitative idea of how and with what factors a disease is forming in an individual and how vulnerable it can become. The different levels of such indicators provide the diagnostic expert to detect the type and extent of a neuropsychiatric disease and determine the risk factors associated with it.

e.g.- In pregnant women Oestrogen-mediated epigenetic DNA methylation pattern leads to high risk of post-partum depression (Guintivano *et.al.,* 2014).

**5.2.2. Biomarkers of diagnosis or trait:**

Diagnostic biomarkers ensure the presence of certain neuropsychiatric disease. A good diagnostic biomarker will signify only one type of disorder. E.g.- Diagnostic biomarker for Alzheimer’s disease is senile plaques and neurofibrillary tangles (Schwarz *et.al.,*2012).

* + 1. **Biomarkers of acuity:**

The severity of a particular disease is measurable with the presence of a biomarker at particular state. E.g.- expression of IL-6, IL-10, neurotrophin-3, protein carbonyl etc. are associated with acute episodes of mania in bipolar disorder(Kapczinski *et.al.*, 2010).

* + 1. **Biomarkers of stage:**

Categorization of exact stage of illness is assured by the biomarkers of stage. In neuropsychiatric disorder analysis detection of particular stage is very crucial. E.g.- amyloidβ1-42 and tau proteins are associated with mild cognitive impairment and easily derived from cerebro spinal fluid of a patient (Lewczuk *et.al.*, 2010).

* + 1. **Biomarkers of treatment response:**

After administration of drug or treatment, treatment response biomarkers are easily found in individuals system. E.g.- elevated levels of cytokine is associated with antidepressant effects of exercise (Rethrost *et.al.*, 2013)

* + 1. **Biomarkers of prognosis:**

The prediction of likely course and outcome of an illness is detected by prognostic biomarkers. The expression of such biomarkers enables the clinician to detect the proper dosage for treatment. E.g.- major depressive disorder patients are likely to show more TNFα and IL-6 expression and poor response to antidepressant therapy (Krishnadas and Cavanag, 2012).

1. **Biomarkers for hepatic diseases**

Liver is the largest internal organ in a human body. It is responsible for majority of metabolism as well as detoxification functions of drug and other diverse environmental chemicals (Klaassen, 2007). Liver cells are frequently exposed to toxicants of significant concentrations which can adversely affect their specific functions. For example- a commonly used analgesic and antipyretic drug in USA is acetaminophen (Hinson *et.ai.*, 2010). This particular drug upon overexposure leads in production of highly reactive hepatotoxic compounds (Lee,2004). Apart from drugs, hepatic cells often encounter toxicity due to metabolic substances, ingested metal, environmental toxicants etc. as well. Hepatic diseases are often termed as Drug induced liver injury (DILI) caused by high intake of oral drugs (Kaplowitz, 2005). A number of biomarkers are associated with DILI. According to FDA guidelines, a combination of four biomarkers is considered as an indicative measure for DILI (FDA, 2009). ALT (Alanine aminotransferase), AST (Aspartate aminotransferase), ALP (Alkaline phosphatase) and TBL (Total Bilirubin) are the four indicative biomarkers used by clinicians for detection of DILI (Yang *et.al.*, 2014). Apart from these four biomarkers different hepatotoxic diseases can be identified using specific biomarkers. The table below enlists some of the most common hepatotoxic diseases and the biomarkers associated to them.

|  |  |  |
| --- | --- | --- |
| Sl. No. | Biomarker | Name of disease |
|  | ALT | Hepatocellular necrosis (ALT is most commonly used marker); ALT is also increased due to heart and skeletal muscle injury. |
|  | ALP | Cholestasis (drug induced), Hepatobiliary injury. |
|  | TBL (disease severity indicator) | Cholestasis, Hepatobiliary, Haemolysis |
|  | AST | Hepatocellular necrosis (ASP is less common than ALT), Extra hepatic tissue injury. |
|  | GGT (Gamma- glutamyltransferase) | Cholestasis, Biliary |
|  | Triglyceride clotting time | Failure of bile elimination, severe hepatic injury |
|  | Urobillinogen | Biliary obstruction in liver (the marker is found in urine) |
|  | Ammonia | Liver injury |
|  | Albumin | Chronic liver disease (indicated by decrease in albumin) |

Ref: Ozer *et.al.*,2008

Apart from these conventional biomarkers, via Omics technique more specific biomarkers for each individual hepatic disease are being discovered in recent times. The need of specificity along with the common biomarkers is the driving force acting behind such specific and detailed experiments by the clinicians. The classification of hepatotoxic biomarkers based on the platforms used for omics are broadly-

1. Genetics biomarker of hepatotoxicity
2. Genomics biomarker of hepatotoxicity
3. Proteonomics biomarker of hepatotoxicity
4. Metabolomics biomarker of hepatotoxicity and
5. MicroRNAs as biomarker of hepatotoxicity.

The discovery of such emerging biomarkers is making the diagnosis not only easier for the practitioners but accurate as well. Some of the examples of emerging hepatotoxicity biomarkers are given below in tabular format.

|  |  |  |  |
| --- | --- | --- | --- |
| Sl. No. | Biomarker | Disease | Reference |
|  | Glutathione S-transferase P-form | Hepatocellular injury | Fella et al., 2005; Gluckmann et al., 2007 |
| 2. | IL-1 | Cellular response to tissue damage | Akbay et al., 1999; Lacour et al., 2005 |
| 3. | Paraoxanase 1 (Found in kindey, brain and lung as well) | Hepatocellular necrosis | Amacher et al., 2005; Schomaker et al., 2013 |
| 4. | Apolipoprotein E (also found in brain and kidney) | Hepatocellular necrosis | Ozer et al., 2008; Andersson et al., 2009; Bell et al., 2012 |
| 5. | Glutathione S-transferase alpha (Liver specific) | Hepatocellular necrosis | Giffen et al., 2002 |
| 6. | Purine nucleoside phosphorylase (mainly present in Kupffer cells, hepatocytes and endothelial cells of liver) | Hepatocellular necrosis | Amacher et al., 2005; Schomaker et al., 2013 |
| 7. | Acylcarnitines | Failure of fatty acid oxidation | Chen et al., 2009; Zhang et al., 2011 |
| 8. | 5-Oxoproline | Oxidative stress and glutathione status | Kumar et al., 2010; Xiong et al., 2012 |
| 9. | miRNA-122 | Viral-, alcohol- and chemical-induced liver injury; hepatocarcinoma | Wang et al., 2009; Starkey Lewis et al., 2011; Ding et al., 2012 |
| 10. | miR-291a-5p | Chemical-induced liver injury | Yang et al., 2012b |
| 11. | miRNA-192 | Chemical-induced liver injury | Wang et al., 2009 |
| 12. | Steroids | Oxidative stress and liver damage | Chen et al., 2009; Kumar et al., 2011; Xiong et al., 2012 |

1. **Biomarkers for Genetic Diseases**

The common conception of genetic disorders in a non medical person is often limited with rare, single gene related commonly observed disorders like cystic fibrosis (CS), Hemophilia, Alzheimer’s, Phenylketonuria or some forms of cancer (when a family history of the disease has been diagnosed clearly). But in reality, the genetic basis of disorder is a much larger field of concern. Not only genetic constitution of an individual but other factors like environmental effectors, lifestyle of a particular individual, exposure to certain reactive substances, pathogenic infection, exposure to certain biological agents etc. often leads to critical genetic disorders. Genetic diseases are diagnosed based on certain genomic trait evaluation. The evaluation used to include assays to detect genetic variants in the diseased individual, in a particular population. Regulatory agencies (CHMP/ICH/437986/ 2006) has very recently introduced the application of genomic biomarkers (GB) for detection of genetic diseases. These GBs are ought to reflect the features of 1. Expression of a gene, 2. Function of a gene and 3. Regulation of genes. Such detailed data on the genetic variants make GBs an important tool for disease diagnosis. GB discovery has thus become a core of interest for both academicians and medical based industries. For a long time period, GBs were used only for diagnosis of genetic disorders with single gene mutations like- familial hypercholesterolemia, hyperkalemia, high blood pressure etc. Polygenic origin of diseases lacking Mendelian pattern of transmission are however difficult to detect using GBs as these are often related to complex environmental factors. Multiple GBs are associated with drug response factors and are termed as genetic biomarkers for response. Some of such examples are-

|  |  |  |  |
| --- | --- | --- | --- |
| Sl. No. | Biomarker | Disease | Treatment associated |
|  | UGT1A1 | Colon cancer | Irinotecan therapy |
| 2. | CYP2C9/VKORC1 | Anticoagulant treatment | Warfarin dose |
| 3. | HLA-B\*5701 | Hypersensitivity syndrome | Abacavir |
| 4. | Philadelphia chromosome | Lymphoblastic leukemia | Gleevec |
| 5. | Her2/neu | Breast cancer | Herceptin |

Ref: Novelli *et.al.*, 2008

1. **Precision Medicine and Biomarkers: An Insight into Modern Healthcare:**

Precision medicine is a cutting edge approach relying heavily on molecular information and tailored therapeutic strategies to devise individualized treatments in healthcare sector. Biomarkers play a pivotal role in steering this Novel branch where they act as an indicator of diagnostic, prognostic and therapeutic responses. In recent years, the use of terms like "precision medicine" and "personalized medicine" has seen a significant uptick, integrating into routine clinical procedures and understanding. Evolution of biomarkers went hand in hand with personalized medicine. In its early manifestations, precision medicine application revolved around tailoring of medical treatment based on individual patient characteristics. To better grasp the idea of personalized medicine, let's consider a few examples. Historically, tackling infectious diseases required pinpointing the responsible organism and then choosing an effective antimicrobial treatment. When it comes to bacterial infections, this approach is well-established, as thoughtful and empirical antibiotic use has been the norm for a long time. However, the introduction of precision medicine in identifying bacteria or viruses at the point-of-care, especially with insights into their potential sensitivities, could be groundbreaking. Such advancements may expedite and refine treatments, minimizing the risk of antimicrobial resistance. (Jameson 2015). Major application of precision medicine came in the field of medical oncology. For example- In lung cancer apart from the routine classification based on histopathology is augmented by *EGFR* mutation and amplification ,CK18 expression, KRAS mutation(De Petris et al. 2011; Adderley, Blackhall, and Lindsay 2019; N. Yan et al. 2022; Bethune et al. 2010) . ALK fusion genes are uncommon, comprising less than 5% in Non-small cell lung cancer (Jameson 2015). Tumors with ALK rearrangements don't overlap with those having EGFR or KRAS mutations. This unique scenario epitomizes the concept of 'oncogene dependency,' where a singular gene product can induce malignancy. These ALK rearrangements are more prevalent in distinct demographics, particularly younger individuals who have minimal or no smoking history. Using targeted treatments like Crizotinib offers a more favorable prognosis for such patients (Chan and Hughes 2015). A multi disciplinary approach has been made in the field of precision medicine ,it has been enriched by genetics, informatics, and imaging, along with other technologies such as proteomics, epigenetics ,metamolobimcs and transcriptomics which are rapidly expanding the scope of Precsison medicine(Bravo-Merodio et al. 2021b).A significant milestone in the journey of precision medicine: the Human Genome Project (HGP) from 1990 to 2003, coupled with the HapMap project initiated in 2002. These groundbreaking projects enabled profound insights into fundamental genome functions, particularly in the exploration, detection, and profiling of polymorphisms, known as SNPs. The advent of genomic screening technologies paved the way for matching the appropriate medications with the right individuals, birthing the domain of pharmacogenomics. This area has become an integral pillar of personalized medicine. The FDA has endorsed 51 distinct pharmacogenetic correlations that aid in therapeutic decisions. Warfarin, an anticoagulant used to treat blood clotting, serves as a prime example in this context whose therapeutic dose depends upon *CYP2C9, CYP4F2, VKORC*1 variants.

8.1 **Biomarkers: Bridging the Gap:** In clinical scenarios, biomarkers play a crucial role in evaluating patients, including gauging the likelihood of diseases and initial screening for cancers. These biomarkers can distinguish between benign and malignant growths, as well as differentiate various cancer types. They are pivotal in establishing a diagnosis, forecasting prognosis, and predicting patient responses post-treatment. One of the notable applications of biomarkers is their ability to ascertain an individual's susceptibility to cancer. For instance, in cases where a woman has a pronounced familial history of ovarian cancer, she might opt for genetic tests to check for specific hereditary mutations, like BRCA1. Possessing this mutation elevates her chances of developing both breast and ovarian cancers (Henry and Hayes 2012). Biomarkers often serve as indicative tools for specific treatments. Take, for instance, the KRAS mutation. KRAS operates as a predictive biomarker, given that its somatic mutations correlate with a diminished responsiveness to therapies targeting the epidermal growth factor receptor (EGFR)(Henry and Hayes 2012). In Chronic Myelogenous Leukemia (CML) BCR-ABL fusion which occurred due to chromosomal translocation from Chromosome 22 of *BCR* geneto chromosome 9 of *ABL* gene resulted in BCR-ABL fusion protein (Henry and Hayes 2012). In 2001, Imatinib, also recognized by its brand names "Gleevec" or "Glivec" and identified as a BCR-ABL tyrosine kinase inhibitor, transformed the landscape of chronic myeloid leukemia (CML) treatment, earning it the moniker "magic bullet" (Iqbal and Iqbal 2014). Biomarkers also have a pivotal role in gauging the efficacy of chemotherapy. For instance, circulating soluble protein tumor markers like CEA, PSA, CA125, as well as MUC-1 antigens CA15-3 and CA27.29, and CA19-9, are recommended to track the therapeutic response in metastatic cancers of the colorectal, prostate, ovarian, breast, and pancreas, respectively

**8.2 Applications in Neurological Disorders:** Alzheimer's disease stands out as one of the most common neurological disorders. This intricate neurodegenerative condition is marked by an escalating decline in cognitive functions, which affects day-to-day activities. Symptoms include significant memory lapses and changes in both spatial and temporal awareness. It's estimated that around 14 million individuals across Europe and the United States are impacted by this ailment(Lewczuk et al. 2020). Hence, specific biomarkers are necessary for early diagnosis and prognosis along with the medical intervention needed to improve quality of life. Alzheimer's disease is notably characterized by two primary markers: neuritic plaques, which are composed of the Amyloid-β peptide (Aβ), and neurofibrillary tangles (NFTs), which are formed from hyperphosphorylated Tau protein (pTau). Four cerebrospinal fluid (CSF) biomarkers commonly referenced in relation to this disease are Amyloid beta 42 (Aβ42), the Aβ42/40 ratio, Tau protein, and Tau phosphorylated at threonine 181 (pTau181), as detailed in Lewczuk et al. 2020. An observable reduction in CSF Aβ42 levels and/or the Aβ42/40 ratio, coupled with increased CSF concentrations of Tau and/or pTau, predominantly signify the dual pathophysiological processes of Alzheimer's disease, namely amyloidosis and neurodegeneration. A number of Novel CSF biomarkers have been investigated which are specific for pathologic changes whereas some indicate oxidative damage or inflammation this includes β-site amyloid precursor protein cleaving enzyme 1 (BACE1), Heart-type fatty acid-binding protein (hFABP), Chitinase-3-like protein 1 (YKL-40) Increased in CSF and plasma ,Interferon-γ-induced protein 10 (IP-10), Matrix metalloproteinase-9 and -3 (MMP-9 and MMP-3), Synaptosome-associated protein 25 (SNAP-25), α-Synuclein, TDP-43, Visinin-like protein 1 (VILIP-1) and Neuroflament light (NF-L)(Lewczuk et al. 2020). In therapeutic studies, NfL (Neurofilament protein) has been employed as a biomarker for ALS and is integrated into standard clinical diagnostic practices (Reddy and Abeygunaratne 2022). Parkinson's disease (PD) is a progressively debilitating neurodegenerative disorder caused by the deterioration of dopaminergic neurons in the Substantia Nigra pars Compacta (SNc) and the accumulation of Lewy bodies, which are unusual protein aggregates. This condition impacts over 10 million individuals globally. While environmental factors play a role, the genetic underpinnings of both familial and sporadic PD forms have been deeply researched. Families with monogenic hereditary PD variants often possess mutations in the SNCA (4q22.1, α-synuclein) gene. Notably, frequent mutations associated with PD include those in PARK2 (6q26, Parkin) and PINK1 (1p36.12, PTEN-induced putative kinase 1), which are typically inherited as autosomal dominant traits. In contrast, mutations in DJ1 (1p36.23, Protein Deglycase DJ-1) are seen in autosomal recessive forms.(Strafella et al. 2018). A comprehensive analysis of five GWAS (Genome-Wide Association Studies) highlighted eleven associated loci, which include SNPs from SNCA, LRRK2, GBA (1q22, Glucosidase β), and HLA-DRB5 (6p21.32, Major histocompatibility complex, class II, DR β-5). The varying response to PD medications among individuals can be modulated by particular genetic elements. The pharmacogenomics of PD medications primarily focuses on genes associated with dopaminergic activity, including dopamine receptors (DRD1, DRD2, DRD3), transporters (DAT, SLC22A1/OCT1), and enzymes crucial for dopamine metabolism and breakdown (COMT, MAO-B, DDC). Of the dopamine receptor genes, DRD2 has been the most studied. Research indicates that patients possessing the DRD2 13 and 14 repeat alleles (CA) of an intronic Short-Tandem Repeat (STR) exhibited a diminished risk of LID. In contrast, those with the DRD2 15 repeat allele showed more favorable disease outcomes,hence precsion medicine can analyse the overall data and generate an omics profile for a better 360 degrees overview of patient (Strafella et al. 2018) .

**8.3** **Personalized Treatment: Presicon Medicine's Crowning Glory:**  It will be really fascinating to imagine a world where medical treatment is as unique as one's fingerprint. Using genomic and molecular information, clinicians can now determine how individuals might respond to a treatment by adopting an error free approach. The current imperative is a sweeping research initiative that fosters innovation within the realm of precision medicine, conducts meticulous clinical trials, and consequently establishes a foundation of evidence that will steer clinical practices (Collins and Varmus 2015). Precision medicine's nuanced molecular approach towards cancer will complement and refine, rather than supplant, the prevailing successful oncological methodologies related to prevention, diagnostics, certain screening techniques, and efficacious treatments. This will solidify a resilient structure to expedite the incorporation of precision medicine in other domains, with inherited genetic disorders and infectious diseases being at the forefront of these areas

1. **CONCLUSION:**

Biological markers are the latest diagnostic measure in clinical practices. Due to specificity of expression at each stage both prognosis and diagnosis of complex diseases have become easier with accuracy. Application of ‘Omics’ in determination of biomarkers is not only specific but a rapid process. Both diagnostic industries and research laboratories are focusing on these techniques for better output. Recent day techniques for precision medicine depend majorly on molecular methods. In this chapter we have elaborately described about the properties of biomarkers, types of biomarkers, list of biomarkers associated to particular diseases, prognostic and diagnostic biomarkers of particular diseases and biomarkers in precision medicine. It is to be concluded that biomarkers due to their accuracy, can be regarded as one of the best diagnostic tool for uni as well as multi-factorial complex diseases. Determination of stage and extent of a complex disease at genetic or protein level makes the diagnosis easier and treatment becomes more specific by the clinicians. More upcoming experiments on this particular field will enable the medical practitioners and researchers with easiness and accuracy of detection and diagnosis.

**REFERENCES:**

Abbritti, Rosaria Viola, Francesca Polito, Maria Cucinotta, Claudio Lo Giudice, Maria Caffo, Chiara Tomasello, Antonino Germanò, and Mohammed Aguennouz. 2016. “Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.” Cancer Genomics.

Abdel-Hafiz, Samah Mamdouh, Hussam EM Hamdy, Fatma M Khorshed, Tarek S Aboushousha, Gehan Safwat, mohamed A Saber, Mohamed Seleem, and Amira H Soliman. 2018. “Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis.” Asian Pacific Journal of Cancer Prevention 19 (4). https://doi.org/10.22034/APJCP.2018.19.4.1021.

Adderley, Helen, Fiona H. Blackhall, and Colin R. Lindsay. 2019. “KRAS-Mutant Non-Small Cell Lung Cancer: Converging Small Molecules and Immune Checkpoint Inhibition.” EBioMedicine 41 (March): 711–16. https://doi.org/10.1016/j.ebiom.2019.02.049.

Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. 2010. Incidental Lewy body disease: Clinical comparison to a control cohort. Mov Disord 25: 642–646.

Affandi, Khairunisa Ahmad, Nur Maya Sabrina Tizen, Muaatamarulain Mustangin, and Reena Rahayu MdReena Rahayu Md Zin. 2018. “P40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma.” Journal of Pathology and Translational Medicine 52 (5): 283–89. https://doi.org/10.4132/jptm.2018.08.14.

Afzal, Samia, Muhammad Hassan, Safi Ullah, Hazrat Abbas, Farah Tawakkal, and Mohsin Ahmad Khan. 2022. “Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications.” Frontiers in Molecular Biosciences 9 (February): 783450. https://doi.org/10.3389/fmolb.2022.783450.

Akdis, Deniz, Liang Chen, Ardan M. Saguner, Ningning Zhang, Joanna Gawinecka, Lanja Saleh, Arnold Von Eckardstein, et al. 2022. “Novel Plasma Biomarkers Predicting Biventricular Involvement in

Alcalde, Mireia, Rocío Toro, Fernando Bonet, José Córdoba-Caballero, Estefanía Martínez-Barrios, Juan Antonio Ranea, Marta Vallverdú-Prats, et al. 2023. “Role of MicroRNAs in Arrhythmogenic Cardiomyopathy: Translation as Biomarkers into Clinical Practice.” Translational Research 259 (September): 72–82. https://doi.org/10.1016/j.trsl.2023.04.003.

Alcon, Sophie, Antoine Talarmin, Monique Debruyne, Andrew Falconar, Vincent Deubel, and Marie Flamand. 2002. “Enzyme-Linked Immunosorbent Assay Specific to Dengue Virus Type 1 Nonstructural Protein NS1 Reveals Circulation of the Antigen in the Blood during the Acute Phase of Disease in Patients Experiencing Primary or Secondary Infections.” Journal of Clinical Microbiology 40 (2): 376–81. https://doi.org/10.1128/JCM.40.02.376-381.2002.

Alexander Guminski. 2021. “Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor: From

Amaral, Maria João, Rui Caetano Oliveira, Paulo Donato, and José Guilherme Tralhão. 2023. “Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics—A Review.” Digestive Diseases and Sciences 68 (7): 2811–23. https://doi.org/10.1007/s10620-023-07904-6.

Andrew Connelly. n.d. “Measurement of Troponin in Cardiomyopathies.”

Anghel, Larisa, Radu Sascău, Ioana Mădălina Zota, and Cristian Stătescu. 2021. “Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-Ischemic Dilated Cardiomyopathy.” International Journal of Molecular Sciences 22 (11): 5688. https://doi.org/10.3390/ijms22115688.

Arnold, Melina, Christian C. Abnet, Rachel E. Neale, Jerome Vignat, Edward L. Giovannucci, Katherine A. McGlynn, and Freddie Bray. 2020. “Global Burden of 5 Major Types of Gastrointestinal Cancer.” Gastroenterology 159 (1): 335-349.e15. https://doi.org/10.1053/j.gastro.2020.02.068.

Arrhythmogenic Right Ventricular Cardiomyopathy.” American Heart Journal 244 (February): 66–76. https://doi.org/10.1016/j.ahj.2021.10.187.

Arul V. Chandran3., Shiva Kumar R. Mukkamalla. n.d. “Mukkamalla SKR, Winters R, Chandran AV. Tracheal Cancer. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: Https://Www.Ncbi.Nlm.Nih.Gov/Books/NBK538437/.” July 4, 2023.

Atallah, Ghofraan Abdulsalam, Nor Haslinda Abd Aziz, Chew Kah Teik, Mohamad Nasir Shafiee, and Nirmala Chandralega Kampan. 2021. “New Predictive Biomarkers for Ovarian Cancer.” Diagnostics (Basel, Switzerland) 11 (3): 465. https://doi.org/10.3390/diagnostics11030465.

Atroosh, Wahib M., Yee-Ling Lau, Georges Snounou, Meram Azzani, and Hesham M. Al-Mekhlafi. 2022. “Plasmodium Falciparum Histidine Rich Protein 2 (Pfhrp2): An Additional Genetic Marker Suitable for Anti-Malarial Drug Efficacy Trials.” Malaria Journal 21 (1): 2. https://doi.org/10.1186/s12936-021-04014- 4.

Banno, Kouji, Iori Kisu, Megumi Yanokura, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, et al. 2012. “Biomarkers in Endometrial Cancer: Possible Clinical Applications (Review).” Oncology Letters 3 (6): 1175–80. https://doi.org/10.3892/ol.2012.654.

Barresi, Valeria, Antonio Ieni, Giovanni Branca, and Giovanni Tuccari. 2014. “Brachyury: A Diagnostic Marker for the Differential Diagnosis of Chordoma and Hemangioblastoma versus Neoplastic Histological Mimickers.” Disease Markers 2014: 1–7. https://doi.org/10.1155/2014/514753.

Barriuso, Jorge, Ana Custodio, Ruth Afonso, Vicente Alonso, Aurora Astudillo, Jaume Capdevila, Rocío García-Carbonero, et al. 2018. “Prognostic and Predictive Biomarkers for Somatostatin Analogs, Peptide Receptor Radionuclide Therapy and Serotonin Pathway Targets in Neuroendocrine Tumours.” Cancer Treatment Reviews 70 (November): 209–22. https://doi.org/10.1016/j.ctrv.2018.09.008.

Battaglini, Denise, Miquéias Lopes-Pacheco, Hugo C. Castro-Faria-Neto, Paolo Pelosi, and Patricia R. M. Rocco. 2022. “Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19.” Frontiers in Immunology 13 (April): 857573. https://doi.org/10.3389/fimmu.2022.857573.

Baudi, Ian, Takako Inoue, and Yasuhito Tanaka. 2020. “Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi.” International Journal of Molecular Sciences 21 (3): 949. https://doi.org/10.3390/ijms21030949.

Beenken, Samuel W., William E. Grizzle, D. Ralph Crowe, Michael G. Conner, Heidi L. Weiss, Marty T. Sellers, Helen Krontiras, Marshall M. Urist, and Kirby I. Bland. 2001. “Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-ErbB-2 and P53:” Annals of Surgery 233 (5): 630–38. https://doi.org/10.1097/00000658-200105000-00006.

Bethune, Gillian, Drew Bethune, Neale Ridgway, and Zhaolin Xu. 2010. “Epidermal Growth Factor

BIOMECA Study.” Neuro-Oncology, March, noad055. https://doi.org/10.1093/neuonc/noad055.

Bodegraven, Emma J., Jessy V. Asperen, Pierre A.J. Robe, and Elly M. Hol. 2019. “Importance of GFAP Isoform‐specific Analyses in Astrocytoma.” Glia 67 (8): 1417–33. https://doi.org/10.1002/glia.23594.

Bonnin, Jose M. 2019. “Predictive Biomarkers and Targeted Therapies in Adult Brain Cancers.” In Predictive Biomarkers in Oncology, edited by Sunil Badve and George Louis Kumar, 383–91. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-319-95228-4\_34.

Bravo-Merodio, L.; Acharjee, A.; Russ, D.; Bisht, V.; Williams, J. A.; Tsaprouni, L. G.; Gkoutos, G. V. Translational Biomarkers in the Era of Precision Medicine. In Advances in Clinical Chemistry; Elsevier, 2021; Vol. 102, pp 191–232. https://doi.org/10.1016/bs.acc.2020.08.002.

Bravo-Merodio, Laura, Animesh Acharjee, Dominic Russ, Vartika Bisht, John A. Williams, Loukia G. 2021b. “Translational Biomarkers in the Era of Precision Medicine.” In Advances in Clinical Chemistry, 102:191–232. Elsevier. https://doi.org/10.1016/bs.acc.2020.08.002.

Brito-Zerón, Pilar, Chiara Baldini, Hendrika Bootsma, Simon J. Bowman, Roland Jonsson, Xavier Mariette, Kathy Sivils, Elke Theander, Athanasios Tzioufas, and Manuel Ramos-Casals. 2016. “Sjögren Syndrome.” Nature Reviews Disease Primers 2 (1): 16047. https://doi.org/10.1038/nrdp.2016.47.

Brunetti, Oronzo, Antonio Gnoni, Antonella Licchetta, Vito Longo, Angela Calabrese, Antonella Argentiero, Sabina Delcuratolo, Antonio Giovanni Solimando, Andrea Casadei-Gardini, and Nicola

Cambronero, F., F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip. 2008. Biomarkers of Pathophysiology in Hypertrophic Cardiomyopathy: Implications for Clinical Management and Prognosis.” European Heart Journal 30 (2): 139–51. https://doi.org/10.1093/eurheartj/ehn538.

Cercelaru, Liliana, and A.E. Stepan. 2017. “P53 Immunoexpression in Laryngeal Squamous Cell Carcinoma.” Current Health Sciences Journal, no. 4 (December): 325–29. https://doi.org/10.12865/CHSJ.43.04.06.

Chalela, Roberto, Víctor Curull, César Enríquez, Lara Pijuan, Beatriz Bellosillo, and Joaquim Gea. 2017. “Lung Adenocarcinoma: From Molecular Basis to Genome-Guided Therapy and Immunotherapy.” Journal of Thoracic Disease 9 (7): 2142–58. https://doi.org/10.21037/jtd.2017.06.20.

Chan, Bryan A, and Brett G M Hughes. 2015. “Targeted Therapy for Non-Small Cell Lung Cancer: Current Standards and the Promise of the Future.” Translational Lung Cancer Research 4 (1).

Chapman, Rebecca J, David R Ghasemi, Felipe Andreiuolo, Valentina Zschernack, Arnault Tauziede Espariat, Francesca R Buttarelli, Felice Giangaspero, et al. 2023. “Optimizing Biomarkers for Accurate Ependymoma Diagnosis, Prognostication, and Stratification within International Clinical Trials: A

Chaube, Amita, Mallika Tewari, Usha Singh, and H.S. Shukla. 2006. “CA 125: A Potential Tumor Marker for Gallbladder Cancer.” Journal of Surgical Oncology 93 (8): 665–69. https://doi.org/10.1002/jso.20534.

Chen, Lin, Qiaodan Zhou, Junjie Liu, and Wei Zhang. 2021. “CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.” Frontiers in Immunology 12 (October): 759565. https://doi.org/10.3389/fimmu.2021.759565.

Chen, Weiqian, Heng Cao, Jin Lin, Nancy Olsen, and Song Guo Zheng. 2015. “Biomarkers for Primary Sjögren’s Syndrome.” Genomics, Proteomics & Bioinformatics 13 (4): 219–23. https://doi.org/10.1016/j.gpb.2015.06.002.

Collins, Francis S., and Harold Varmus. 2015. “A New Initiative on Precision Medicine.” New England Journal of Medicine 372 (9): 793–95. https://doi.org/10.1056/NEJMp1500523.

Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes.” Life 12 (9): 1403. https://doi.org/10.3390/life12091403.

Conroy, Andrea L., Margarita Gélvez, Michael Hawkes, Nimerta Rajwans, Vanessa Tran, W. Conrad Liles, Luis Angel Villar-Centeno, and Kevin C. Kain. 2015. “Host Biomarkers Are Associated with Progression to Dengue Haemorrhagic Fever: A Nested Case-Control Study.” International Journal of Infectious Diseases 40 (November): 45–53. https://doi.org/10.1016/j.ijid.2015.07.027.

Craniopharyngioma.” Journal of Neuro-Oncology 131 (1): 21–29. https://doi.org/10.1007/s11060-016- 2273-z.

Crocetti, Emanuele, Annalisa Trama, Charles Stiller, Adele Caldarella, Riccardo Soffietti, Jana Jaal, Damien C. Weber, Umberto Ricardi, Jerzy Slowinski, and Alba Brandes. 2012. “Epidemiology of Glial and Non-Glial Brain Tumours in Europe.” European Journal of Cancer 48 (10): 1532–42. https://doi.org/10.1016/j.ejca.2011.12.013.

Custodio, Ana, and Jaime Feliu. 2013. “Prognostic and Predictive Biomarkers for Epidermal Growth Factor Receptor-Targeted Therapy in Colorectal Cancer: Beyond KRAS Mutations.” Critical Reviews in Oncology/Hematology 85 (1): 45–81. https://doi.org/10.1016/j.critrevonc.2012.05.001.

De Petris, Luigi, Eva Brandén, Richard Herrmann, Betzabe Chavez Sanchez, Hirsh Koyi, Barbro

De Silva, Madhawa, Sameer Rastogi, David Chan, Christopher Angel, Owen Prall, Anthony Gill, and

De, Ji, Yi Shen, Jinyu Qin, Li Feng, Yiping Wang, and Li Yang. 2016. “A Systematic Review of Des-γ- Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma.” Medicine 95 (17): e3448. https://doi.org/10.1097/MD.0000000000003448.

Der(16)t(1;16), and Enhanced MYC Expression in the Absence of Gene Amplification.” Cancer Genetics and Cytogenetics 100 (2): 159–64. https://doi.org/10.1016/S0165-4608(97)00030-7.

Diagnostic Dilemma to Novel Personalised Therapy in 2 Case Reports.” Translational Cancer Research 10 (7): 3588–99. https://doi.org/10.21037/tcr-21-131.

Dimitrow, P P, A Undas, M Bober, W Tracz, and J S Dubiel. 2008. “Obstructive Hypertrophic Cardiomyopathy Is Associated with Enhanced Thrombin Generation and Platelet Activation.” Heart 94 (6): e21–e21. https://doi.org/10.1136/hrt.2007.126896.

Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG. 2014a. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 20: 525–529.

Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017 Jul 5;9(7):a028035. doi: 10.1101/cshperspect.a028035. PMID: 28062563; PMCID: PMC5495060.

Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, Caviness JN, Belden C, Driver- Dunckley E, Davis KJ, et al. 2014c. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol 73: 244–252.

Dunckley, T.; Coon, K. D.; Stephan, D. A. Discovery and Development of Biomarkers of Neurological Disease. Drug Discov. Today 2005, 10 (5), 326–334. https://doi.org/10.1016/S1359-6446(04)03353-7.

Dunckley, Travis, Keith D. Coon, and Dietrich A. Stephan. 2005. “Discovery and Development of Biomarkers of Neurological Disease.” Drug Discovery Today 10 (5): 326–34. https://doi.org/10.1016/S1359-6446(04)03353-7.

Empting LD. Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure. Toxicol Ind Health. 2009 Oct-Nov;25(9-10):577-81. doi: 10.1177/0748233709348393. PMID: 19854819.

Erkan, Erdogan Pekcan, Thomas Ströbel, Christian Dorfer, Markus Sonntagbauer, Andreas Weinhäusel, Nurten Saydam, and Okay Saydam. 2019. “Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation.” Frontiers in Oncology 9 (October): 1031. https://doi.org/10.3389/fonc.2019.01031.

Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. 2011. Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP? Parkinsonism Relat Disord 17: 365–371.

F. De Wilde, Fausto J. Rodriguez, et al. 2012. “Frequent ATRX , CIC , FUBP1 and IDH1 Mutations Refine the Classification of Malignant Gliomas.” Oncotarget 3 (7): 709–22. https://doi.org/10.18632/oncotarget.588.

Fassbach, M., and B. Schwartzkopff. 2005. “Elevated Serum Markers for Collagen Synthesis in Patients with Hypertrophic Cardiomyopathy and Diastolic Dysfunction.” Zeitschrift Für Kardiologie 94 (5): 328– 35. https://doi.org/10.1007/s00392-005-0214-5.

FDA (2009) FDA guidance for industry. Drug-induced liver injury. Premarketing clinical evaluation. [www.fda.gov/Drugs/](http://www.fda.gov/Drugs/) GuidanceComplianceRegulatoryInformation/Guidances/ ucm064993.htm.

Fenton, Kristin Andreassen, and Hege Lynum Pedersen. 2023. “Advanced Methods and Novel Biomarkers in Autoimmune Diseases ‑ a Review of the Recent Years Progress in Systemic Lupus Erythematosus.” Frontiers in Medicine 10 (June): 1183535. https://doi.org/10.3389/fmed.2023.1183535.

Foko, Loick Pradel Kojom, Geetika Narang, Suman Tamang, Joseph Hawadak, Jahnvi Jakhan, Amit Sharma, and Vineeta Singh. 2022. “The Spectrum of Clinical Biomarkers in Severe Malaria and New Avenues for Exploration.” Virulence 13 (1): 634–53. https://doi.org/10.1080/21505594.2022.2056966.

Folic, Miljan M., Ana V. Banko, Vera N. Todorovic, Nela S. Puskas, Jovica P. Milovanovic, Sanja B. Krejovic, Neda Z. Dragicevic-Babic, et al. 2022. “The Expression of Hypoxia-Related Biomarkers: A Significance of HIF-1α C1772T Polymorphism as Predictor of Laryngeal Carcinoma Relapse.” Cancer Control 29 (January): 107327482211444. https://doi.org/10.1177/10732748221144457.

Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, et al. 2011. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 32: 857–863.

Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, et al. 2011. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 32: 857–863.

Gao, Lixia, Xuli Wang, Yaoliang Tang, Shuang Huang, Chien-An Andy Hu, and Yong Teng. 2017. “FGF19/FGFR4 Signaling Contributes to the Resistance of Hepatocellular Carcinoma to Sorafenib.” Journal of Experimental & Clinical Cancer Research 36 (1): 8. https://doi.org/10.1186/s13046-016-0478- 9.

García-Gutiérrez, M. S.; Navarrete, F.; Sala, F.; Gasparyan, A.; Austrich-Olivares, A.; Manzanares, J. Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality. Front. Psychiatry 2020, 11, 432. https://doi.org/10.3389/fpsyt.2020.00432.

García-Gutiérrez, Maria Salud, Francisco Navarrete, Francisco Sala, Ani Gasparyan, Amaya Austrich- Olivares, and Jorge Manzanares. 2020. “Biomarkers in Psychiatry: Concept, Definition, Types and

Germinoma.” Am J Surg Pathol 29 (3).

Gibb WR, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752.

Goletti, Delia, Elisa Petruccioli, Simone A. Joosten, and Tom H.M. Ottenhoff. 2016. “Tuberculosis Biomarkers: From Diagnosis to Protection.” Infectious Disease Reports 8 (2): 6568. https://doi.org/10.4081/idr.2016.6568.

Gong, Jian, Haili Zhang, Shushan Xing, Chunde Li, Zhenyu Ma, Ge Jia, and Wanning Hu. 2014. “High Expression Levels of CXCL12 and CXCR4 Predict Recurrence of Adamanti-Nomatous Craniopharyngiomas in Children.” Cancer Biomarkers 14 (4): 241–51. https://doi.org/10.3233/CBM-140397.

Goschzik, Tobias, Edward C Schwalbe, Debbie Hicks, Amanda Smith, Anja Zur Muehlen, Dominique Figarella-Branger, François Doz, et al. 2018. “Prognostic Effect of Whole Chromosomal Aberration Signatures in Standard-Risk, Non-WNT/Non-SHH Medulloblastoma: A Retrospective, Molecular Analysis of the HIT-SIOP PNET 4 Trial.” The Lancet Oncology 19 (12): 1602–16. https://doi.org/10.1016/S1470-2045(18)30532-1.

Gossage, Lucy, and Tim Eisen. 2010. “Alterations in VHL as Potential Biomarkers in Renal-Cell Carcinoma.” Nature Reviews Clinical Oncology 7 (5): 277–88. https://doi.org/10.1038/nrclinonc.2010.42.

Gossing, Wilhelm, Marcus Frohme, and Lars Radke. 2020. “Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors.” Biomedicines 8 (6): 148. https://doi.org/10.3390/biomedicines8060148.

Gousias, K., A. J. Becker, M. Simon, and P. Niehusmann. 2012. “Nuclear Karyopherin A2: A Novel Biomarker for Infiltrative Astrocytomas.” Journal of Neuro-Oncology 109 (3): 545–53. https://doi.org/10.1007/s11060-012-0924-2.

Guaraldi, Giovanni, Marianna Meschiari, Alessandro Cozzi-Lepri, Jovana Milic, Roberto Tonelli, Marianna Menozzi, Erica Franceschini, et al. 2020. “Tocilizumab in Patients with Severe COVID-19: A Retrospective Cohort Study.” The Lancet Rheumatology 2 (8): e474–84. https://doi.org/10.1016/S2665- 9913(20)30173-9.

Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry 2014; 19: 560–567.

Hara, Akira, Masayuki Niwa, Tomohiro Kanayama, Kei Noguchi, Ayumi Niwa, Mikiko Matsuo, Takahiro

Hasegawa, Koji, Hisayoshi Fujiwara, Masatoshi Koshiji, Tsukasa Inada, Seiji Ohtani, Kiyoshi Doyama, Masaru Tanaka, et al. 1996. “Endothelin-1 and Its Receptor in Hypertrophic Cardiomyopathy.” Hypertension 27 (2): 259–64. https://doi.org/10.1161/01.HYP.27.2.259.

Hasegawa, Yasuhisa, Mitsuo Goto, Nobuhiro Hanai, Taijiro Ozawa, and Hitoshi Hirakawa. 2017. “Predictive Biomarkers for Combined Chemotherapy with 5‑fluorouracil and Cisplatin in Oro‑ and Hypopharyngeal Cancers.” Molecular and Clinical Oncology, November. https://doi.org/10.3892/mco.2017.1521.

Hattab, Eyas M, Pang-Hsien Tu, Jon D Wilson, and Liang Cheng. 2005. “OCT4 Immunohistochemistry Is Superior to Placental Alkaline Phosphatase (PLAP) in the Diagnosis of Central Nervous System

Henry, N. Lynn, and Daniel F. Hayes. 2012. “Cancer Biomarkers.” Molecular Oncology 6 (2): 140–46. https://doi.org/10.1016/j.molonc.2012.01.010.

Hinson, J.A., Roberts, D.W., and James, L.P. (2010) Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 196: 369405.

Hsu, Chiun, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice

Hu, Ying, Wanzhen Chen, Zhanpeng Yan, Jingxia Ma, Fangshi Zhu, and Jiege Huo. 2019. “Prognostic Value of PD-L1 Expression in Patients with Pancreatic Cancer: A PRISMA-Compliant Meta-Analysis.” Medicine 98 (3): e14006. https://doi.org/10.1097/MD.0000000000014006.

Huss, Sebastian, Helen Pasternack, Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Birthe Heitkötter, Wolfgang Hartmann, Marcel Trautmann, et al. 2017. “Clinicopathological and Molecular Features of a Large Cohort of Gastrointestinal Stromal Tumors (GISTs) and Review of the Literature: BRAF Mutations in KIT/PDGFRA Wild-Type GISTs Are Rare Events.” Human Pathology 62 (April): 206–14. https://doi.org/10.1016/j.humpath.2017.01.005.

Hussaini, Mohammad. 2015. “Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology.” Cancer Control 22 (2): 158–66. https://doi.org/10.1177/107327481502200206.

Hwang, Hyundoo, Boo-Young Hwang, and Juan Bueno. 2018. “Biomarkers in Infectious Diseases.” Disease Markers 2018 (June): 1–2. https://doi.org/10.1155/2018/8509127.

Incorvaia, Lorena, Daniele Fanale, Bruno Vincenzi, Ida De Luca, Tommaso Vincenzo Bartolotta, Roberto Cannella, Gianni Pantuso, et al. 2021. “Type and Gene Location of KIT Mutations Predict Progression- Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon.” Cancers 13 (5): 993. https://doi.org/10.3390/cancers13050993.

Iqbal, Nida, and Naveed Iqbal. 2014. “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.” Molecular Biology International 2014 (September): 1–9. https://doi.org/10.1155/2014/852748.

Ivanova, Mariia, Konstantinos Venetis, Elena Guerini-Rocco, Luca Bottiglieri, Mauro Giuseppe Mastropasqua, Ornella Garrone, Nicola Fusco, and Michele Ghidini. 2022. “HER2 in Metastatic

Jameson, J Larry. 2015. “Precision Medicine — Personalized, Problematic, and Promising.” N Engl j Med.

Jansen, M., I. Christiaans, S. N. Van Der Crabben, M. Michels, R. Huurman, Y. M. Hoedemaekers, D. Dooijes, et al. 2021. “BIO FOr CARE: Biomarkers of Hypertrophic Cardiomyopathy Development and Progression in Carriers of Dutch Founder Truncating MYBPC3 Variants—Design and Status.” Netherlands Heart Journal 29 (6): 318–29. https://doi.org/10.1007/s12471-021-01539-w.

Jennifer L. Clarke, et al. 2017. “Histopathologic Review of Pineal Parenchymal Tumors Identifies Novel Morphologic Subtypes and Prognostic Factors for Outcome.” Neuro-Oncology 19 (1): 78–88. https://doi.org/10.1093/neuonc/now105.

Jiao, Yuchen, Patrick J. Killela, Zachary J. Reitman, B. Ahmed Rasheed, Christopher M. Heaphy, Roeland

John, Daisy Vanitha, Yee-Shin Lin, and Guey Chuen Perng. 2015. “Biomarkers of Severe Dengue Disease – a Review.” Journal of Biomedical Science 22 (1): 83. https://doi.org/10.1186/s12929-015-0191-6.

Ju, Mengyang, Xiaolin Ge, Xiaoke Di, Yumeng Zhang, Liang Liang, and Yujing Shi. 2022. “Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma.” Frontiers in Oncology 11 (January): 789312. https://doi.org/10.3389/fonc.2021.789312.

Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010; 15: 784– 786.

Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4: 489499.

Kees, Ursula R, Dominic Spagnolo, Lavinia A Hallam, Jette Ford, Pamela R Ranford, David L Baker, David F Callen, and Jaclyn A Biegel. 1998. “A New Pineoblastoma Cell Line, PER-480, with Der(10)t(10;17),

Kim, Hark Kyun, and Jeffrey E Green. 2014. “Predictive Biomarker Candidates for the Response of Gastric Cancer to Targeted and Cytotoxic Agents.” Pharmacogenomics 15 (3): 375–84. https://doi.org/10.2217/pgs.13.250.

Kiyoi, Hitoshi, Naomi Kawashima, and Yuichi Ishikawa. 2020. “FLT3 Mutations in Acute Myeloid

Klaassen, C. (2007) Casarett and Doull’s Toxicology: The Basic Science of Poisons. McGraw Hill Professional, New York.

Ko, Gyung Hyuck, Se-Il Go, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, and Woo Song Ha. 2017. “Prognostic Impact of Ki-67 in Patients with Gastric Cancer—the Importance of Depth of Invasion and Histologic Differentiation.” Medicine 96 (25): e7181. https://doi.org/10.1097/MD.0000000000007181.

Kriegsmann, Katharina, Christiane Zgorzelski, Thomas Muley, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin Eichhorn, et al. 2021. “Role of Synaptophysin, Chromogranin and CD56 in Adenocarcinoma and Squamous Cell Carcinoma of the Lung Lacking Morphological Features of Neuroendocrine Differentiation: A Retrospective Large-Scale Study on 1170 Tissue Samples.” BMC Cancer 21 (1): 486. https://doi.org/10.1186/s12885-021-08140-9.

Krishnadas R, Cavanagh J. Depression: an inflammatory illness?. J Neurol Neurosurg Psychiatry 2012; 83:

Kumar, Nathella Pavan, Arul Nancy, Vijay Viswanathan, Shanmugam Sivakumar, Kannan Thiruvengadam, Shaik Fayaz Ahamed, Syed Hissar, Hardy Kornfeld, and Subash Babu. 2023. “Chitinase and Indoleamine 2, 3-Dioxygenase Are Prognostic Biomarkers for Unfavorable Treatment Outcomes in Pulmonary

Kuroda, Yuichiro Hatano, Hideshi Okada, and Hiroyuki Tomita. 2020. “Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology.” Biomolecules 10 (9): 1277. https://doi.org/10.3390/biom10091277.

Laetsch, Theodore W, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, et al. 2018. “Larotrectinib for Paediatric Solid Tumours Harbouring NTRK Gene Fusions: Phase 1 Results from a Multicentre, Open-Label, Phase 1/2 Study.” The Lancet Oncology 19 (5): 705–14. https://doi.org/10.1016/S1470-2045(18)30119-0.

Lee, W.M. (2004) Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure. Hepatology 40: 69.

Leukemia: Therapeutic Paradigm beyond Inhibitor Development.” Cancer Science 111 (2): 312–22. https://doi.org/10.1111/cas.14274.

Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010; 15: 138–145.

Lewczuk, Piotr, Marta Łukaszewicz-Zając, Piotr Mroczko, and Johannes Kornhuber. 2020. “Clinical Significance of Fluid Biomarkers in Alzheimer’s Disease.” Pharmacological Reports 72 (3): 528–42. https://doi.org/10.1007/s43440-020-00107-0.

Li, Minxia, Fei Xue, Jie Yang, and Xiaodong Pan. 2020. “Correlation between Tumor Marker CA72-4 and Prognosis of Patients with Gastric Cancer: A Protocol for Systematic Review and Meta-Analysis.” Medicine 99 (52): e23723. https://doi.org/10.1097/MD.0000000000023723.

Li, Xiang-Min, Wei-Guo Huang, Hong Yi, Ai-Lan Cheng, and Zhi-Qiang Xiao. 2009. “Proteomic Analysis to Identify Cytokeratin 18 as a Novel Biomarker of Nasopharyngeal Carcinoma.” Journal of Cancer Research and Clinical Oncology 135 (12): 1763–75. https://doi.org/10.1007/s00432-009-0623-3.

Li, Yongxiao, Tao Jiang, Liwei Shao, Yan Liu, Chen Zheng, Yanfeng Zhong, Jing Zhang, and Qing Chang. 2016. “Mir-449a, a Potential Diagnostic Biomarker for WNT Group of Medulloblastoma.” Journal of Neuro-Oncology 129 (3): 423–31. https://doi.org/10.1007/s11060-016-2213-y.

Lim, Ka Young, Kwanghoon Lee, Yumi Shim, Jin Woo Park, Hyunhee Kim, Jeongwan Kang, Jae Kyung

Lim, M. L.; Jungebluth, P.; Macchiarini, P. Regenerative Medicine for Diseases of the Respiratory System. In Translational Regenerative Medicine; Elsevier, 2015; pp 449–456. https://doi.org/10.1016/B978-0-12- 410396-2.00032-3.

Lim, Mei Ling, Philipp Jungebluth, and Paolo Macchiarini. 2015. “Regenerative Medicine for Diseases of the Respiratory System.” In Translational Regenerative Medicine, 449–56. Elsevier. https://doi.org/10.1016/B978-0-12-410396-2.00032-3.

Linderholm, Rolf Lewensohn, Stig Linder, and Janne Lehtiö. 2011. “Diagnostic and Prognostic Role of Plasma Levels of Two Forms of Cytokeratin 18 in Patients with Non-Small-Cell Lung Cancer.” European Journal of Cancer 47 (1): 131–37. https://doi.org/10.1016/j.ejca.2010.08.006.

Liu, Du-Hu. 2001. “Expression of Vascular Endothelial Growth Factor and Its Role in Oncogenesis of Human Gastric Carcinoma.” World Journal of Gastroenterology 7 (4): 500. https://doi.org/10.3748/wjg.v7.i4.500.

Liu, Fang, Lin Li, MengDa Xu, Juan Wu, Ding Luo, YuSi Zhu, BiXi Li, XiaoYang Song, and Xiang Zhou. 2020. “Prognostic Value of Interleukin-6, C-Reactive Protein, and Procalcitonin in Patients with COVID-19.” Journal of Clinical Virology 127 (June): 104370. https://doi.org/10.1016/j.jcv.2020.104370.

Liu, Shuai, Zhisheng Huang, Xiaoyan Deng, Xiaohui Zou, Hui Li, Shengrui Mu, and Bin Cao. 2021. Identification of Key Candidate Biomarkers for Severe Influenza Infection by Integrated Bioinformatical Analysis and Initial Clinical Validation.” Journal of Cellular and Molecular Medicine 25 (3): 1725–38. https://doi.org/10.1111/jcmm.16275.

Liu, X., and K.-M. Chu. 2019. “Molecular Biomarkers for Prognosis of Gastrointestinal Stromal Tumor.” Clinical and Translational Oncology 21 (2): 145–51. https://doi.org/10.1007/s12094-018-1914-4.

Louati, Sara, Nadia Senhaji, Laila Chbani, and Sanae Bennis. 2018. “EWSR1 Rearrangement and CD99 Expression as Diagnostic Biomarkers for Ewing/PNET Sarcomas in a Moroccan Population.” Disease Markers 2018 (September): 1–5. https://doi.org/10.1155/2018/7971019.

Lu, Yining, Collin M Labak, Neha Jain, Ian J Purvis, Maheedhara R Guda, Sarah E Bach, Swapna Asuthkar, and Kiran K Velpula. n.d. “OTX2 Expression Contributes to Proliferation And.”

M. Mehnert, et al. 2017. “Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.” Journal of Clinical Oncology 35 (36): 4050–56. https://doi.org/10.1200/JCO.2017.73.3675.

M. Stankovic. 2020. “MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas.” Frontiers in Cellular Neuroscience 14 (July): 191. https://doi.org/10.3389/fncel.2020.00191.

Ma, Yunfeng, Ya Zhang, Yu Bi, Longmei He, Dandan Li, Dan Wang, Mengying Wang, and Xiaoqin Wang. 2022. “Diagnostic Value of Carcinoembryonic Antigen Combined with Cytokines in Serum of Patients with Colorectal Cancer.” Medicine 101 (37): e30787. https://doi.org/10.1097/MD.0000000000030787.

Maheshwari, Amita, Neha Kumar, and Umesh Mahantshetty. 2016. “Gynecological Cancers: A Summary of Published Indian Data.” South Asian Journal of Cancer 05 (03): 112–20. https://doi.org/10.4103/2278- 330X.187575.

Manterola, Lorea, Elizabeth Guruceaga, Jaime Gállego Pérez-Larraya, Marisol González-Huarriz, Patricia Jauregui, Sonia Tejada, Ricardo Diez-Valle, et al. 2014. “A Small Noncoding RNA Signature Found in Exosomes of GBM Patient Serum as a Diagnostic Tool.” Neuro-Oncology 16 (4): 520–27. https://doi.org/10.1093/neuonc/not218.

Masson, S. 2006. “Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal ProBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data.” Clinical Chemistry 52 (8): 1528–38. https://doi.org/10.1373/clinchem.2006.069575.

Matthia, Eldon L., Michael L. Setteducato, Mohammed Elzeneini, Nicholas Vernace, Michael Salerno, Christopher M. Kramer, and Ellen C. Keeley. 2022. “Circulating Biomarkers in Hypertrophic Cardiomyopathy.” Journal of the American Heart Association 11 (23): e027618. https://doi.org/10.1161/JAHA.122.027618.

Mayeux, R. Biomarkers: Potential Uses and Limitations. 2004, 1 (2).

Mayeux, Richard. 2004. “Biomarkers: Potential Uses and Limitations” 1 (2).

McKenna, William J., Barry J. Maron, and Gaetano Thiene. 2017. “Classification, Epidemiology, and Global Burden of Cardiomyopathies.” Circulation Research 121 (7): 722–30. https://doi.org/10.1161/CIRCRESAHA.117.309711.

Mittal, Shweta, and Saurabh Bansal. 2020. “Expression of Ki-67 in Early Glottic Carcinoma and Its Relation to Oncological Outcomes Following CO 2 Laser Microsurgery.” Journal of Carcinogenesis 19 (1): 7. https://doi.org/10.4103/jcar.JCar\_7\_20.

Montano, Nicola, Tonia Cenci, Maurizio Martini, Quintino Giorgio D’Alessandris, Federica Pelacchi, Lucia Ricci-Vitiani, Giulio Maira, Ruggero De Maria, Luigi Maria Larocca, and Roberto Pallini. 2011. “Expression

Moreno-Acosta, Pablo, Schyrly Carrillo, Oscar Gamboa, Alfredo Romero-Rojas, Jinneth Acosta, Monica Molano, Joseph Balart-Serra, Martha Cotes, Chloé Rancoule, and Nicolas Magné. 2016. “Novel Predictive Biomarkers for Cervical Cancer Prognosis.” Molecular and Clinical Oncology 5 (6): 792–96. https://doi.org/10.3892/mco.2016.1055.

Motegi, Atsushi, Shinji Sakurai, Hiroko Nakayama, Takaaki Sano, Tetsunari Oyama, and Takashi Nakajima. 2005. “PKC Theta, a Novel Immunohistochemical Marker for Gastrointestinal Stromal Tumors (GIST), Especially Useful for Identifying KIT-Negative Tumors.” Pathology International 55 (3): 106–12. https://doi.org/10.1111/j.1440-1827.2005.01806.x.

Nakayama, Izuma, Toru Hirota, and Eiji Shinozaki. 2020. “BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation.” Cancers 12 (11): 3236. https://doi.org/10.3390/cancers12113236.

Nix, P, L Cawkwell, H Patmore, J Greenman, and N Stafford. 2005. “Bcl-2 Expression Predicts Radiotherapy Failure in Laryngeal Cancer.” British Journal of Cancer 92 (12): 2185–89. https://doi.org/10.1038/sj.bjc.6602647.

Nixon, Daniel E, and Alan L Landay. 2010. “Biomarkers of Immune Dysfunction in HIV:” Current Opinion in HIV and AIDS 5 (6): 498–503. https://doi.org/10.1097/COH.0b013e32833ed6f4.

Njoku, Kelechi, Chloe E. Barr, and Emma J. Crosbie. 2022. “Current and Emerging Prognostic Biomarkers in Endometrial Cancer.” Frontiers in Oncology 12 (April): 890908. https://doi.org/10.3389/fonc.2022.890908.

Nocini, Riccardo, Gabriele Molteni, Camilla Mattiuzzi, Giuseppe Lippi, Section of Ear Nose and Throat (ENT), Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona 37134, Italy, Service of Clinical Governance, Provincial Agency for Social and Sanitary Services, Trento 38123, Italy, and Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona 37134, Italy. 2020. “Updates on Larynx Cancer Epidemiology.” Chinese Journal of Cancer Research 32 (1): 18–25. https://doi.org/10.21147/j.issn.1000-9604.2020.01.03.

Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008 May;5(2):149-54. PMID: 22460999; PMCID: PMC2781197.

O’Neill, Robert S, and Alina Stoita. 2021. “Biomarkers in the Diagnosis of Pancreatic Cancer: Are We Closer to Finding the Golden Ticket?” World Journal of Gastroenterology 27 (26): 4045–87. https://doi.org/10.3748/wjg.v27.i26.4045.

Oakley, Gerard J, Kim Fuhrer, and Raja R Seethala. 2008. “Brachyury, SOX-9, and Podoplanin, New Markers in the Skull Base Chordoma vs Chondrosarcoma Differential: A Tissue Microarray-Based Comparative Analysis.” Modern Pathology 21 (12): 1461–69. https://doi.org/10.1038/modpathol.2008.144.

of EGFRvIII in Glioblastoma: Prognostic Significance Revisited.” Neoplasia 13 (12): 1113-IN6. https://doi.org/10.1593/neo.111338.

Ostertag, C. B., B. Volk, T. Shibata, P. Burger, and P. Kleihues. 1987. “The Monoclonal Antibody Ki-67 as a Marker for Proliferating Cells in Stereotactic Biopsies of Brain Tumours.” Acta Neurochirurgica 89 (3–4): 117–21. https://doi.org/10.1007/BF01560376.

Park, Jong-Ho, Young Min Woo, Emilia Moonkyung Youm, Nada Hamad, Hong-Hee Won, Kazuhito Naka, Eun-Ju Park, et al. 2019. “HMGCLL1 Is a Predictive Biomarker for Deep Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia.” Leukemia 33 (6): 1439–50. https://doi.org/10.1038/s41375-018- 0321-8.

Park, Sin Young, Sang Jae Roh, Yo Na Kim, Sung Zoo Kim, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Myoung Jae Kang, Dong Geun Lee, and Woo Sung Moon. 2009. “Expression of MUC1, MUC2, MUC5AC and MUC6 in Cholangiocarcinoma: Prognostic Impact.” Oncology Reports 22 (3): 649–57. https://doi.org/10.3892/or\_00000485.

Pavicevic, Sandra, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik P. Modest, Uwe Pelzer, et al. 2022. “Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.” Cancers 14 (4): 1026. https://doi.org/10.3390/cancers14041026.

Pawloski, Jacob A., Hassan A. Fadel, Yi-Wen Huang, and Ian Y. Lee. 2021. “Genomic Biomarkers of Meningioma: A Focused Review.” International Journal of Molecular Sciences 22 (19): 10222. https://doi.org/10.3390/ijms221910222.

Penicka, M., P. Gregor, J. Krupicka, and M. Jira. 2001. “Tumour Necrosis Factor-Alpha Soluble Receptors Type I Are Related to Symptoms and Left Ventricular Function in Hypertrophic Cardiomyopathy.” The Canadian Journal of Cardiology 17 (7): 777–84.

Perera, F. P.; Weinstein, I. B. Molecular Epidemiology: Recent Advances and Future Directions. Carcinogenesis 2000, 21 (3), 517–524. https://doi.org/10.1093/carcin/21.3.517.

Perera, Frederica P., and I.Bernard Weinstein. 2000. “Molecular Epidemiology: Recent Advances and Future Directions.” Carcinogenesis 21 (3): 517–24. https://doi.org/10.1093/carcin/21.3.517.

Petruccioli, Elisa, Thomas J. Scriba, Linda Petrone, Mark Hatherill, Daniela M. Cirillo, Simone A. Joosten, Tom H. Ottenhoff, Claudia M. Denkinger, and Delia Goletti. 2016. “Correlates of Tuberculosis Risk: Predictive Biomarkers for Progression to Active Tuberculosis.” European Respiratory Journal 48 (6): 1751–63. https://doi.org/10.1183/13993003.01012-2016.

Pino, Maria S., and Daniel C. Chung. 2010. “The Chromosomal Instability Pathway in Colon Cancer.” Gastroenterology 138 (6): 2059–72. https://doi.org/10.1053/j.gastro.2009.12.065.

Plum, Patrick Sven, Florian Gebauer, Max Krämer, Hakan Alakus, Felix Berlth, Seung-Hun Chon, Lars Schiffmann, et al. 2019. “HER2/Neu (ERBB2) Expression and Gene Amplification Correlates with Better Survival in Esophageal Adenocarcinoma.” BMC Cancer 19 (1): 38. https://doi.org/10.1186/s12885-018- 5242-4.

Prada-Arismendy, Jeanette, Johanna C. Arroyave, and Sarah Röthlisberger. 2017. “Molecular Biomarkers in Acute Myeloid Leukemia.” Blood Reviews 31 (1): 63–76. https://doi.org/10.1016/j.blre.2016.08.005.

Pratt, Drew, Felix Sahm, and Kenneth Aldape. 2021. “DNA Methylation Profiling as a Model for Discovery and Precision Diagnostics in Neuro-Oncology.” Neuro-Oncology 23 (Supplement\_5): S16–29. https://doi.org/10.1093/neuonc/noab143.

Prince, H. E. Biomarkers for Diagnosing and Monitoring Autoimmune Diseases. Biomarkers 2005, 10 (sup1), 44–49. https://doi.org/10.1080/13547500500214194.

Prince, Harry E. 2005. “Biomarkers for Diagnosing and Monitoring Autoimmune Diseases.” Biomarkers 10 (sup1): 44–49. https://doi.org/10.1080/13547500500214194.

Rai, Ashutosh, Soujanya D. Yelamanchi, Bishan D. Radotra, Sunil K. Gupta, Kanchan K. Mukherjee, Manjul Tripathi, Rajesh Chhabra, et al. 2022. “Phosphorylation of β-Catenin at Serine552 Correlates with Invasion and Recurrence of Non-Functioning Pituitary Neuroendocrine Tumours.” Acta Neuropathologica Communications 10 (1): 138. https://doi.org/10.1186/s40478-022-01441-5.

Rajkumar, S. Vincent. 2020. “Multiple Myeloma: 2020 Update on Diagnosis, Risk‐stratification and Management.” American Journal of Hematology 95 (5): 548–67. https://doi.org/10.1002/ajh.25791.

Raleigh, David R., David A. Solomon, Shane A. Lloyd, Ann Lazar, Michael A. Garcia, Penny K. Sneed,

Ram, Bhed, and Ramna Thakur. 2022. “Epidemiology and Economic Burden of Continuing Challenge of Infectious Diseases in India: Analysis of Socio-Demographic Differentials.” Frontiers in Public Health 10 (June): 901276. https://doi.org/10.3389/fpubh.2022.901276.

Receptor (EGFR) in Lung Cancer: An Overview and Update.” Journal of Thoracic Disease 2 (1): 48–51.

Reddy, Doodipala Samba, and Hasara Nethma Abeygunaratne. 2022. “Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders.” International Journal of Molecular Sciences 23 (19): 11734. https://doi.org/10.3390/ijms231911734.

Relevance to the Clinical Reality.” Frontiers in Psychiatry 11 (May): 432. https://doi.org/10.3389/fpsyt.2020.00432.

Ren, Yin, Hiroshi Hyakusoku, Jessica E. Sagers, Lukas D. Landegger, D. Bradley Welling, and Konstantina

Rene R. Diaz4. and Kristen N. Brown1. n.d. “Brown KN, Pendela VS, Ahmed I, et al. Restrictive Cardiomyopathy. [Updated 2023 Jul 30.” 2023 Jan. https://[www.ncbi.nlm.nih.gov/books/NBK537234/.](http://www.ncbi.nlm.nih.gov/books/NBK537234/)

Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013; 18: 1119–1124.

Riad, Alexander, Stefan Gross, Jeannine Witte, Rico Feldtmann, Katharina B. Wagner, Yvonne Reinke, Kerstin Weitmann, et al. 2018. “MD-2 Is a New Predictive Biomarker in Dilated Cardiomyopathy and Exerts Direct Effects in Isolated Cardiomyocytes.” International Journal of Cardiology 270 (November): 278–86. https://doi.org/10.1016/j.ijcard.2018.06.025.

Roesler, Rafael, Barbara Kunzler Souza, and Gustavo R. Isolan. 2021. “Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.” International Journal of Molecular Sciences 22 (21): 11352. https://doi.org/10.3390/ijms222111352.

Rubino, Franco, Christopher Alvarez-Breckenridge, Kadir Akdemir, Anthony P. Conley, Andrew J. Bishop, Wei-Lien Wang, Alexander J. Lazar, Laurence D. Rhines, Franco DeMonte, and Shaan M. Raza. 2022. Prognostic Molecular Biomarkers in Chordomas: A Systematic Review and Identification of Clinically Usable Biomarker Panels.” Frontiers in Oncology 12 (September): 997506. https://doi.org/10.3389/fonc.2022.997506.

Rubio Caballero, M., A. Nogués Biau, M. Falguera Sacrest, and T. Puig Ganau. 1999. “[The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients].” Anales De Medicina Interna (Madrid, Spain: 1984) 16 (9): 447–50.

Sarhadi, Virinder Kaur, and Gemma Armengol. 2022. “Molecular Biomarkers in Cancer.” Biomolecules 12 (8): 1021. https://doi.org/10.3390/biom12081021.

Sasmita, Andrew Octavian, Ying Pei Wong, and Anna Pick Kiong Ling. n.d. “Biomarkers and Therapeutic Advances in Glioblastoma Multiforme.”

Schindler, Genevieve, David Capper, Jochen Meyer, Wibke Janzarik, Heymut Omran, Christel Herold- Mende, Kirsten Schmieder, et al. 2011. “Analysis of BRAF V600E Mutation in 1,320 Nervous System Tumors Reveals High Mutation Frequencies in Pleomorphic Xanthoastrocytoma, Ganglioglioma and Extra-Cerebellar Pilocytic Astrocytoma.” Acta Neuropathologica 121 (3): 397–405. https://doi.org/10.1007/s00401-011-0802-6.

Schlüter, Anke, Patrick Weller, Oliver Kanaan, Ivonne Nel, Lukas Heusgen, Benedikt Höing, Pia Haßkamp, et al. 2018. “CD31 and VEGF Are Prognostic Biomarkers in Early-Stage, but Not in Late-Stage, Laryngeal Squamous Cell Carcinoma.” BMC Cancer 18 (1): 272. https://doi.org/10.1186/s12885-018-4180-5.

Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. 2000. “Preclinical” AD revisited: Neuropathology of cognitively normal older adults. Neurology 55: 370–376.

Schneider, Constanze, Thomas Oellerich, Hanna-Mari Baldauf, Sarah-Marie Schwarz, Dominique Thomas, Robert Flick, Hanibal Bohnenberger, et al. 2017. “SAMHD1 Is a Biomarker for Cytarabine Response and a Therapeutic Target in Acute Myeloid Leukemia.” Nature Medicine 23 (2): 250–55. https://doi.org/10.1038/nm.4255.

Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494–502

Shapiro, Samantha C. 2021. “Biomarkers in Rheumatoid Arthritis.” Cureus, May. https://doi.org/10.7759/cureus.15063.

Shukla, Neerav. 2013. “Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children’s Oncology Group.” Frontiers in Oncology 3. https://doi.org/10.3389/fonc.2013.00141.

Silvestris. 2019. “Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.” Medicina 55 (10): 707. https://doi.org/10.3390/medicina55100707.

Singh, Alka, Atreyi Pramanik, Pragyan Acharya, and Govind K. Makharia. 2019. “Non-Invasive Biomarkers for Celiac Disease.” Journal of Clinical Medicine 8 (6): 885. https://doi.org/10.3390/jcm8060885.

Smith, Edward R., Michael Manfredi, R. Michael Scott, Peter M. Black, and Marsha A. Moses. 2007. “A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: CASE report.” Neurosurgery 60 (6): E1148–49. https://doi.org/10.1227/01.NEU.0000255464.37634.3C.

Soliman, Amro M., Srijit Das, and Seong Lin Teoh. 2021. “Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.” International Journal of Molecular Sciences 22 (14): 7470. https://doi.org/10.3390/ijms22147470.

Song, Li-Bing, Mu-Sheng Zeng, Wen-Ting Liao, Ling Zhang, Hao-Yuan Mo, Wan-Li Liu, Jian-Yong Shao, et al. 2006. “Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells.” Cancer Research 66 (12): 6225–32. https://doi.org/10.1158/0008-5472.CAN-06-0094.

Sözütek, Didem, Serdar Yanık, Ayşe Neslin Akkoca, Alper Sözütek, Zeynep Tuba Ozdemir, Ciğdem Usul Avşar, Meral Günaldı, Berksoy Sahin, and Figen Doron. 2014. “Diagnostic and Prognostic Roles of DOG1 and Ki-67, in GIST Patients with Localized or Advanced/Metastatic Disease.” International Journal of Clinical and Experimental Medicine 7 (7): 1914–22.

Sparks DL, Danner FW, Davis DG, Hackney C, Landers T, Coyne CM. 1994. Neurochemical and histopathologic alterations characteristic of Pick’s disease in a non-demented individual. J Neuropathol Exp Neurol 53: 37–42.

Strafella, Claudia, Valerio Caputo, Maria R. Galota, Stefania Zampatti, Gianluca Marella, Silvestro Mauriello, Raffaella Cascella, and Emiliano Giardina. 2018. “Application of Precision Medicine in Neurodegenerative Diseases.” Frontiers in Neurology 9 (August): 701. https://doi.org/10.3389/fneur.2018.00701.

Strimbu, K.; Tavel, J. A. What Are Biomarkers?: Curr. Opin. HIV AIDS 2010, 5 (6), 463–466. https://doi.org/10.1097/COH.0b013e32833ed177.

Strimbu, Kyle, and Jorge A Tavel. 2010. “What Are Biomarkers?:” Current Opinion in HIV and AIDS 5 (6): 463–66. https://doi.org/10.1097/COH.0b013e32833ed177.

Su, Zhi Yi, Pui Yan Siak, Chee-Onn Leong, and Shiau-Chuen Cheah. 2023. “The Role of Epstein–Barr Virus in Nasopharyngeal Carcinoma.” Frontiers in Microbiology 14 (February): 1116143. https://doi.org/10.3389/fmicb.2023.1116143.

Sumbly, Vikram, Ian Landry, and Vincent Rizzo. 2022. “Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review.” Cureus, January. https://doi.org/10.7759/cureus.21018.

Sun, Ruifang, L Jeffrey Medeiros, and Ken H Young. 2016. “Diagnostic and Predictive Biomarkers for Lymphoma Diagnosis and Treatment in the Era of Precision Medicine.” Modern Pathology 29 (10): 1118–42. https://doi.org/10.1038/modpathol.2016.92.

Sundblom, Jimmy, Tor Persson Skare, Olivia Holm, Staffan Welin, Madelene Braun, Pelle Nilsson, Per Enblad, Elisabet Ohlin Sjöström, and Anja Smits. 2022. “Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease: Total Growth Rate and Risk of Developing New Lesions Not Associated with Circulating VEGF Levels.” Edited by Prashant Chittiboina. PLOS ONE 17 (11): e0278166. https://doi.org/10.1371/journal.pone.0278166.

Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians 71 (3): 209–49. https://doi.org/10.3322/caac.21660.

Szopa, Wojciech, Thomas A Burley, Gabriela Kramer-Marek, and Wojciech Kaspera. n.d. “Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.” BioMed Research International.

Takami, Hirokazu, and Koichi Ichimura. 2022. “Biomarkers for Risk-Based Treatment Modifications for CNS Germ Cell Tumors: Updates on Biological Underpinnings, Clinical Trials, and Future Directions.” Frontiers in Oncology 12 (September): 982608. https://doi.org/10.3389/fonc.2022.982608.

Tan, Cheng, Xia Qian, Zhifeng Guan, Baixia Yang, Yangyang Ge, Feng Wang, and Jing Cai. 2016. “Potential Biomarkers for Esophageal Cancer.” SpringerPlus 5 (1): 467. https://doi.org/10.1186/s40064-016-2119-

Tao, Lian-Yuan, Lei Cai, Xiao-Dong He, Wei Liu, and Qiang Qu. 2010. “Comparison of Serum Tumor Markers for Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.” The American Surgeon 76 (11): 1210–13.

To, Kelvin K. W., Ivan F. N. Hung, Iris W. S. Li, Kar‐Lung Lee, Chi‐Kwan Koo, Wing‐Wa Yan, Raymond Liu, et al. 2010. “Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection.” Clinical Infectious Diseases 50 (6): 850–59. https://doi.org/10.1086/650581.

Tsaprouni, and Georgios V. Gkoutos. 2021a. “Translational Biomarkers in the Era of Precision Medicine.” In Advances in Clinical Chemistry, 102:191–232. Elsevier. https://doi.org/10.1016/bs.acc.2020.08.002.

Tuberculosis.” Frontiers in Immunology 14 (February): 1093640. https://doi.org/10.3389/fimmu.2023.1093640.

Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. 2006a. Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol 65: 387–395.

Ueda, Yutaka, Takayuki Enomoto, Toshihiro Kimura, Takashi Miyatake, Kiyoshi Yoshino, Masami Fujita, and Tadashi Kimura. 2010. “Serum Biomarkers for Early Detection of Gynecologic Cancers.” Cancers 2 (2): 1312–27. https://doi.org/10.3390/cancers2021312.

Vasileva, Denitsa, and Alaa Badawi. 2019. “C-Reactive Protein as a Biomarker of Severe H1N1 Influenza.” Inflammation Research 68 (1): 39–46. https://doi.org/10.1007/s00011-018-1188-x.

Wang, Sumei, François-Xavier Claret, and Wanyin Wu. 2019. “MicroRNAs as Therapeutic Targets in Nasopharyngeal Carcinoma.” Frontiers in Oncology 9 (August): 756. https://doi.org/10.3389/fonc.2019.00756.

Wang, Yuelong, Jiaojiao Deng, Gang Guo, Aiping Tong, Xirui Peng, Haifeng Chen, Jianguo Xu, Yi Liu, Chao You, and Liangxue Zhou. 2017. “Clinical and Prognostic Role of Annexin A2 in Adamantinomatous

Wang, Z.F., F. Su, X.J. Lin, B. Dai, L.F. Kong, H.W. Zhao, and J. Kang. 2011. “Serum D-Dimer Changes and Prognostic Implication in 2009 Novel Influenza A(H1N1).” Thrombosis Research 127 (3): 198–201. https://doi.org/10.1016/j.thromres.2010.11.032.

Wesseling, Pieter, Martin Van Den Bent, and Arie Perry. 2015. “Oligodendroglioma: Pathology, Molecular Mechanisms and Markers.” Acta Neuropathologica 129 (6): 809–27. https://doi.org/10.1007/s00401-015-1424-1.

Won, et al. 2022. “Molecular Subtyping of Ependymoma and Prognostic Impact of Ki-67.” Brain Tumor Pathology 39 (1): 1–13. https://doi.org/10.1007/s10014-021-00417-y.

Woo, Peter, Alberto Chu, Kwong Chan, and John Kwok. 2017. “Progressive Hemiparesis in a Young Man: Hemicerebral Atrophy as the Initial Manifestation of Basal Ganglia Germinoma.” Asian Journal of Neurosurgery 12 (01): 65–68. https://doi.org/10.4103/1793-5482.145083.

Xiong, Dan-dan, Chu-mei Zeng, Ling Jiang, Dian-zhong Luo, and Gang Chen. 2019. “Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: An Updated Meta-Analysis and Systematic Review Involving 53 Studies and 7078 Patients.” Journal of Cancer 10 (22): 5339–54. https://doi.org/10.7150/jca.30074.

Xu, Cheng, Songhan Ge, Juanxian Cheng, Huabin Gao, Fenfen Zhang, and Anjia Han. 2022. “Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.” Frontiers in Endocrinology 13 (May): 859381. https://doi.org/10.3389/fendo.2022.859381.

Xu, Zhenhua, Najiba Murad, Daniel Malawsky, Ran Tao, Samuel Rivero-Hinojosa, Dörthe Holdhof, Ulrich Schüller, et al. 2022. “OLIG2 Is a Determinant for the Relapse of MYC -Amplified Medulloblastoma.” Clinical Cancer Research 28 (19): 4278–91. https://doi.org/10.1158/1078-0432.CCR-22-0527.

Xue, Xinying, Yuxia Liu, Yong Wang, Mingming Meng, Kaifei Wang, Xuefeng Zang, Sheng Zhao, et al. 2016. “MiR-21 and MiR-155 Promote Non-Small Cell Lung Cancer Progression by Downregulating SOCS1, SOCS6 , and PTEN.” Oncotarget 7 (51): 84508–19. https://doi.org/10.18632/oncotarget.13022.

Yan, Hai, D. Williams Parsons, Genglin Jin, Roger McLendon, B. Ahmed Rasheed, Weishi Yuan, Ivan Kos, et al. 2009. “IDH1 and IDH2 Mutations in Gliomas.” New England Journal of Medicine 360 (8): 765–73. https://doi.org/10.1056/NEJMoa0808710.

Yan, Ningning, Sanxing Guo, Huixian Zhang, Ziheng Zhang, Shujing Shen, and Xingya Li. 2022. “BRAF- Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.” Frontiers in Oncology 12 (March): 863043. https://doi.org/10.3389/fonc.2022.863043.

Yang, Jennifer, Maysa Hamade, Qi Wu, Qin Wang, Robert Axtell, Shailendra Giri, and Yang Mao-Draayer. 2022. “Current and Future Biomarkers in Multiple Sclerosis.” International Journal of Molecular Sciences 23 (11): 5877. https://doi.org/10.3390/ijms23115877.

Yi, Lian, Adam C. Swensen, and Wei-Jun Qian. 2018. “Serum Biomarkers for Diagnosis and Prediction of Type 1 Diabetes.” Translational Research 201 (November): 13–25. https://doi.org/10.1016/j.trsl.2018.07.009.

Yin, Nanchang, and Wei Liu. 2020. “Clinical Value of Tumor Marker Index Based on Preoperative CYFRA 21-1 and SCC-Ag in the Evaluation of Prognosis and Treatment Effectiveness in Patients with Esophageal Squamous Cell Carcinoma.” OncoTargets and Therapy Volume 13 (May): 4135–43. https://doi.org/10.2147/OTT.S243038.

Yoon, Jung Hwan, Yong Gyu Park, Suk Woo Nam, and Won Sang Park. 2019. “The Diagnostic Value of Serum Gastrokine 1 (GKN1) Protein in Gastric Cancer.” Cancer Medicine 8 (12): 5507–14. https://doi.org/10.1002/cam4.2457.

Yu, Haitao, Yasuo Nagafuchi, and Keishi Fujio. 2021. “Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.” Biomolecules 11 (7): 928. https://doi.org/10.3390/biom11070928.

Yu, Hao, Xin Yin, Yiran Mao, Meiqin Chen, Qiuying Tang, and Senxiang Yan. 2022. “The Global Burden of Nasopharyngeal Carcinoma from 2009 to 2019: An Observational Study Based on the Global Burden of Disease Study 2019.” European Archives of Oto-Rhino-Laryngology 279 (3): 1519–33. https://doi.org/10.1007/s00405-021-06922-2.

Yuan, Hai-Liang, Ting Wang, and Kun-He Zhang. 2018. “MicroRNAs as Potential Biomarkers for Diagnosis, Therapy and Prognosis of Gastric Cancer.” OncoTargets and Therapy Volume 11 (July): 3891–3900. https://doi.org/10.2147/OTT.S156921.

Zand, Vahid, Fariba Binesh, Mojtaba Meybodian, Farzan Safi Dahaj, and Arezoo Alamdar Yazdi. 2020. “Cyclin D1 Expression in Patients with Laryngeal Squamous Cell Carcinoma.” Iranian Journal of Pathology 15 (3): 245–50. https://doi.org/10.30699/ijp.2020.116579.2276.

Zen, Kan, Hidekazu Irie, Tomoki Doue, Michitaka Takamiya, Tetsuhiro Yamano, Takahisa Sawada, Akihiro Azuma, and Hiroaki Matsubara. 2005. “Analysis of Circulating Apoptosis Mediators and Proinflammatory Cytokines in Patients With Idiopathic Hypertrophic Cardiomyopathy Comparison Between Nonobstructive and Dilated-Phase Hypertrophic Cardiomyopathy: Comparison Between Nonobstructive and Dilated-Phase Hypertrophic Cardiomyopathy.” International Heart Journal 46 (2): 231–44. https://doi.org/10.1536/ihj.46.231.

Zhang, Yu, Jianfei Long, Junwei Ren, Xiang Huang, Ping Zhong, and Bin Wang. 2021. “Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects.” Frontiers in Oncology 11 (September): 731441. https://doi.org/10.3389/fonc.2021.731441.

Zhou, Fubo, Wenting Shang, Xiaoling Yu, and Jie Tian. 2018. “Glypican-3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment.” Medicinal Research Reviews 38 (2): 741–67. https://doi.org/10.1002/med.21455.

Zhou, Xueyin, Jiasheng Cao, Win Topatana, Tianao Xie, Tianen Chen, Jiahao Hu, Shijie Li, et al. 2023. “Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis.” Immunotherapy 15 (5): 353–65. https://doi.org/10.2217/imt-2022-0168.

Zimmer, Kai, Florian Kocher, Alberto Puccini, and Andreas Seeber. 2021. “Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives.” Frontiers in Oncology 11 (October): 662055. https://doi.org/10.3389/fonc.2021.662055.